

# Withdrawal/Redaction Sheet

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                                                                                                | DATE       | RESTRICTION            |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| 001. email               | From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Levi, Jeffrey W [Personally Identifiable Information] [partial] (1 page)      | 09/17/1996 | b(7)(C), b(7)(F), b(6) |
| 002. email               | From: Jeffrey Levi, To: Remote Addressee, Re: At Last... [personal] [partial] (2 pages)                                                                      | 09/17/1996 | b(6)                   |
| 003. email               | From: Jeffrey Levi, To: Patsy Fleming, Re: Jumping the Gun [personal] [partial] (1 page)                                                                     | 09/18/1996 | b(6)                   |
| 004. email               | From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt. Request for Socarides, Richard C [Personally Identifiable Information] [partial] (1 page) | 09/19/1996 | b(7)(C), b(7)(F), b(6) |
| 005. email               | From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Montoya, Daniel and Others [Personally Identifiable Information] [partial] (1 page)                | 09/19/1996 | b(6)                   |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F

in432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:17-SEP-1996 10:24:00.00

SUBJECT: CDC AIDS Daily Summary 09/17/96

TO: levi\_j ( levi\_j@A1@CD ) (WHO)  
READ:17-SEP-1996 10:39:42.60

TEXT:

AIDS Daily Summary  
September 17, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"AIDS Drug From Glaxo Shows Promise"

"Making Lives Better"

"The Long Road Back to Fitness"

"HIV Drug May Combat Chagas' Disease"

"Drug Boosts Immune System in AIDS Cases--Study"

"Combining Two Similar Drugs Reduces HIV Level in Blood"

"Zimbabwean Women Petition for Cheaper Condoms"

"Uncircumcised Men at Greater AIDS Risk"

"HIV-Related Skin Diseases"

"All-Natural AIDS Protection?"

\*\*\*\*\*

"AIDS Drug From Glaxo Shows Promise"

Wall Street Journal (09/17/96) P. B5; Waldholz, Michael

Results of a preliminary human trial of a new protease inhibitor being developed by Glaxo Wellcome suggest that it may have the same potential as other drugs in the same class. Information from 40 of the 60 subjects who are testing the drug, known as 141W94, was reported by Dr. Robert Schooley of the University of Colorado Medical School at the Interscience Conference on Antimicrobial Agents and Chemotherapy on Monday. Schooley said that the drug reduced the level of virus by about 99 percent in 10 of the test patients who took the drug for four weeks. Moreover, the drug reportedly caused few of the side effects that other protease inhibitors have.

"Making Lives Better"

Miami Herald (09/16/96) P. 1B; Lantigua, John

A second housing facility for low-income AIDS patients in Miami's South Beach will be dedicated this week and will soon provide housing, assistance, and referral services for people with the disease. The building will have 24 units, bringing the total number of such units in Dade County to 337. The Department of Housing and Urban Development funded the project, as well as the renovation of 500 similar units nationwide. To be eligible for the facilities, patients must earn no more than \$15,600 a year. Tenants must pay 30 percent of their income for rent and utilities.

#### "The Long Road Back to Fitness"

Washington Post--Health (09/17/96) P. 8; Newman, Lisa

For former journalist Lisa Newman, the June 21 Philadelphia-to-Washington, D.C. AIDS Ride offered the opportunity to be part of a large AIDS fundraiser while regaining physical fitness. Newman began training for the 300-mile, 3-day ride in April. In nine weeks, she gained eight pounds of muscle and reduced her size from a 12 to an eight. Nationwide, the AIDS Rides are expected to raise more than \$16 million for AIDS service organizations in 10 cities this year.

#### "HIV Drug May Combat Chagas' Disease"

Chicago Tribune (09/16/96) P. 1-7; Goering, Laurie

An anti-fungal drug developed to control candidosis in AIDS patients has been shown to have potential for the treatment of Chagas' disease, a deadly parasitic infection. Researchers at the Venezuela Research Institute recently reported in the journal Science that D0870, or bistrizol, cured the disease in 70 percent to 90 percent of mice treated. Chagas, a disease which affects more than 16 million Latin Americans and kills more than 45,000 people a year, is transmitted to humans by a bite from the vinchuca bug and through blood transfusions from infected people.

#### "Drug Boosts Immune System in AIDS Cases--Study"

Reuters (09/16/96); Kenen, Joanne

A cancer drug, interleukin-2 (IL-2), has been used in low doses to improve immunity in HIV-infected individuals without any apparent side effects. Kendall Smith and colleagues at the New York-Cornell Medical Center report their initial results from a six-month study of 16 patients in today's issue of the Proceedings of the National Academy of Sciences. Larger-scale studies are needed, as well as studies to test the combination of IL-2 with other AIDS drugs. The treatment may be used when people are initially infected with HIV, to help protect the immune system, and for people who are already sick. When used in large doses for chemotherapy against some cancers, IL-2 causes severe side effects; the patients in the trial received small daily doses of the drug, however.

#### "Combining Two Similar Drugs Reduces HIV Level in Blood"

Reuters (09/16/96)

Combining two protease inhibitors has been shown to reduce

the level of HIV in the blood by 99.9 percent, researchers state. Calvin J. Cohen, of Community Research Initiative of New England, reported that, in the second six weeks of tests, patients taking Norvir (ritonavir) and Invirase (saquinavir) showed continued improvement. A total of 136 patients were involved, divided into four different dose groups.

#### "Zimbabwean Women Petition for Cheaper Condoms"

Reuters (09/16/96)

Zimbabwean women are asking the government to make female condoms more accessible and affordable to help curb the spread of HIV. The Zimbabwe Women and AIDS Support Network has initiated a petition, signed by at least 20,000 people. The female condoms cost about \$2, a price too high for many women in the country. Male condoms are distributed free, but women say that men are reluctant to use them.

#### "Uncircumcised Men at Greater AIDS Risk"

United Press International (09/16/96); Susman, Ed

A study of immigrants to Israel has found that uncircumcised men may have a greater risk of contracting HIV because an intact foreskin helps bacteria, including the agents of sexually transmitted diseases, survive. Michael Dan of E. Wolfson Hospital in Israel and colleagues compared the bacterial flora from 125 men who were circumcised when they immigrated with 46 already circumcised men. The researchers found sexually transmitted bacteria almost exclusively in the uncircumcised men.

#### "HIV-Related Skin Diseases"

Lancet (09/07/96) Vol. 348, No. 9028, P. 659; Tschachler, Erwin; Bergstresser, Paul R.; Stingl, Georg

In many HIV-infected individuals, diseases of the skin or mucous membranes are the first signs of disease progression. More than 90 percent of HIV-positive patients develop such conditions--which can include Kaposi's sarcoma, viral and bacterial infections, and other disorders--at some point during their disease. In a review of these diseases, Dr. Erwin Tschachler of the University of Vienna and colleagues discuss the link between immunodeficiency and cutaneous disease pathogenesis. The infection of dendritic cells, Langerhans cells, and dermal dendritic cells in the skin contributes to immunodeficiency. When the skin immune system is impaired, infectious and non-infectious skin diseases occur even before the onset of full immunodeficiency. Up to 75 percent of patients that develop symptomatic infections as a result of HIV infection also develop skin lesions. Viral cofactors that may contribute to disease progression include herpes simplex virus (HSV), which manifests in painful, non-healing ulcers and is different from conventional recurrent HSV infection; varicella-zoster virus; molluscum contagiosum; and human papillomavirus. Bacterial cofactors include staphylococcus aureus, mycobacteria, and syphilis.

#### "All-Natural AIDS Protection?"

Technology Review (08/96-09/96) Vol. 99, No. 6, P. 18

Vaginal foams and creams to protect against pregnancy and sexually transmitted diseases, including HIV, may be developed using natural substances from animals. Magainin Pharmaceuticals, with aid from the National Institutes of Health, is studying the safety and efficacy of two animal-derived compounds for such purposes. Both NIH and the United Nations' World Health Organization have made the development of microbicides a leading priority as the AIDS rate in women continues to rise. The Centers for Disease Control and Prevention reports that there were 14,000 new cases of AIDS among women in 1994, up from 3,700 five years earlier. Vaginal microbicides are targeted because they would give women greater control over their own protection.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-SEP-1996 10:24:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9KYOL7O0G0006O8@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Tue,  
17 Sep 1996 10:23:46 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9KYOE557K0006VD@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Tue, 17 Sep 1996 10:23:36 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9KYLPGCKS00007Y@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Tue, 17 Sep 1996 10:21:25 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA03138; Tue,  
17 Sep 1996 10:23:28 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:17-SEP-1996 12:02:39.86

SUBJECT: RE: Nancy-Ann Meetings and other items

TO: Wm G. White ( Wm G. White@EOP@LNGTWY@EOPMRX )

READ:NOT READ

TEXT:

does she want me at these meetings...i don't need to, only if she  
wants me.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Wm G. White@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:17-SEP-1996 11:07:00.00

SUBJECT: Nancy-Ann Meetings and other items

TO: LEVI\_J ( LEVI\_J@A1@CD ) (WHO)

READ:17-SEP-1996 11:59:52.30

TEXT:

Message Creation Date was at 17-SEP-1996 11:08:00

Sara Bianchi advises that Nancy-Ann is meeting with NORA at 11:00 am tomorrow and AIDS Action at 3:00 pm.

I also confirmed with HRSA that in FY 1996 the ADAP set-aside did not have a SPNS tap and as long as it is continued to be appropriated as an earmark in FY97, it won't have a SPNS either.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Wm G. White@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:17-SEP-1996 13:16:00.00

SUBJECT: RE: Nancy-Ann Meetings and other items

TO: LEVI\_J ( LEVI\_J@A1@CD ) (WHO)

READ:17-SEP-1996 13:20:17.76

TEXT:

Message Creation Date was at 17-SEP-1996 13:15:00

I have not spoken to her today. I'm only hearing this through Sara. I will ask, but if you don't hear anything from me or her, I would assume not.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:17-SEP-1996 11:32:31.77

SUBJECT: RE: Hot issues

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:17-SEP-1996 12:03:54.80

CC: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:17-SEP-1996 13:23:09.93

TEXT:

great, thanks. I'll forward to Cab Affairs and see if they routinely get this.  
If not, it would be great to get updates from you. We do similar exercise for  
crime.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Toby Donenfeld@OVP@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:17-SEP-1996 18:25:00.00

SUBJECT: Thank you for Bill Paul

TO: SANVILLE\_U ( SANVILLE\_U@A1@CD ) (OPD)  
READ:18-SEP-1996 09:36:31.91

TO: LEVI\_J ( LEVI\_J@A1@CD ) (WHO)  
READ:18-SEP-1996 09:06:54.13

TEXT:  
Message Creation Date was at 17-SEP-1996 18:26:00

How's this? Same letter for Varmus minus the second paragraph?

September 17, 1996

Dr. Bill Paul  
Director, Office of AIDS Research  
National Institutes of Health  
Building 31 4CO2  
9000 Rockville Pike  
Bethesda, MD 20892

Dear Dr. Paul:

I wanted to thank you for the briefing you provided to me on Friday, August 2. I appreciated hearing your report from the Vancouver conference and the implications of the new advances in science. I also appreciated receiving the Federal Biomedical Research Plan and Budget and the general update on the progress in the development of vaccines, therapeutics and microbicides.

I also wanted to thank you for personally guiding the development of the first-ever Federal Biomedical Research Plan and Budget for HIV and AIDS. The care and attention provided by you and your staff was instrumental in the successful development of the plan. I appreciate your efforts.

Again, thank you for coming in to meet with me.

Sincerely,

Al Gore



RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME: 17-SEP-1996 12:04:00.00

SUBJECT: New Conference Listings 09/17/96

TO: levi\_j ( levi\_j@AI@CD ) (WHO)

READ: 17-SEP-1996 12:07:04.82

TEXT:

CDC National AIDS Clearinghouse  
Conference Calendar Database

NEW CONFERENCE LISTINGS  
September 17, 1996

The Clearinghouse's Conference Calendar Database contains information about upcoming conferences related to HIV and AIDS.

NAC ONLINE users can search this database by selecting "Clearinghouse Databases" from the NAC ONLINE main menu. When asked to enter a database name, specify "CONF" to search the Calendar.

To access the NAC ONLINE BBS, set your communications software to dial (800) 851-7245, and set the options for 8 data bits, N parity, 1 stop bit, full duplex, and complete a new user questionnaire. Only non-profit organizations, government agencies, educational institutions, and health departments are given full access to NAC ONLINE and the NAC databases.

Overnight, 10 new listings were loaded to the Conference Calendar Database. Their records follow:

TITLE: AIDS, Medicine and Miracles  
DATE: October 10, 1996  
LOCATION: Washington, DC  
SPONSOR(S): AIDS, Medicine and Miracles  
CONTACT: (800) 875-8770; amm@csd.net  
EVENT TYPE: Seminar  
TOPICS: Spirituality. Alternative therapies. Holistic therapies.  
NOTES: Fee: \$25.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops  
DATE: September 18, 1996  
LOCATION: Fresno, CA

SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshop  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops

DATE: September 20, 1996  
LOCATION: Sacramento, CA  
SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshops  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops

DATE: September 25, 1996  
LOCATION: Monterey, CA  
SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshops  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops

DATE: September 30, 1996  
LOCATION: Redding, CA  
SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshops  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops

DATE: October 2, 1996  
LOCATION: Oakland, CA  
SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshops  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Community Challenge Grant Program: Funding Local Solutions to  
Reduce Teen and Unwed Pregnancies; Technical Assistance  
Workshops

DATE: October 8, 1996  
LOCATION: Los Angeles, CA  
SPONSOR(S): California Department of Health Services  
CONTACT: Department of Health Services, c/o CSUS Business Services  
Bureau, 7750 College Town Dr., Ste. 102, Sacramento, CA 95826-  
2344, (916) 278-4960, (800) 858-7743, FAX: (916) 278-4865  
EVENT TYPE: Workshops  
TOPICS: Funding sources. Financial issues. Adolescent pregnancy.  
Community organizations.

TITLE: Issues in Adolescent Health and Research: HIV-Positive Youth and  
the Ethics of Partner Notification

DATE: September 18, 1996  
LOCATION: Washington, DC  
SPONSOR(S): N.E. Place  
CONTACT: Mary Williams, N.E. Place Administrator, (202) 635-6535  
EVENT TYPE: Forum  
TOPICS: Adolescents with HIV/AIDS. Community organizations.  
Networking. HIV prevention.

TITLE: HIV Women's Conference; 5th Annual

DATE: October 19, 1996  
LOCATION: Irvine, CA  
SPONSOR(S): AIDS Walk Orange County; Fountain Valley Regional Hospital;  
Immune Response Corporation; Costa Mesa Pharmacy (VIW Luncheon);  
County of Orange Health Care Agency; Glaxo Wellcome; Merck;  
Roche Laboratories; University of California Irvine--Health  
Education  
CONTACT: Women and HIV Conference, AIDS Services Foundation, 17982 Sky  
Park Circle, Ste. J, Irvine, CA 92615, (714) 253-1500  
EVENT TYPE: Conference  
TOPICS: Women. Treatment. Gynecology. Advocacy. Opportunistic  
infections. Case management. Care gives. Nutrition.  
Spirituality. Death or dying. Families.  
NOTES: Fee: \$35; Health care professionals, \$45; Students (must provide  
copy of student ID), \$15. Additional \$10 when registering at the  
door. Continuing education credits available.

TITLE: Empowering the Disadvantaged: Social Justice in Public Health  
DATE: November 17-21, 1996  
LOCATION: New York, NY  
SPONSOR(S): American Public Health Association  
CONTACT: American Public Health Association, Two Columbus Circle, 6th  
Floor, New York, NY 10019, (202) 789-5646, FAX: (212) 484- 1280,  
World Wide Web home page: <http://www.apha.org>  
EVENT TYPE: Conference  
TOPICS: Community organizations. Mental health services. Sexually  
transmitted diseases (STDs). Women. Counseling. Antibody  
tests. Epidemiology. Substance abuse. Tuberculosis (TB).  
Health care services. Health care availability. Nutrition.  
Developing nations. Children. Pregnancy. Perinatal  
transmission. Treatment.

Information about additional conferences is welcome. Please send  
E-Mail to Flynn McLean (through NAC ONLINE, or  
[fmclean@cdcnac.aspensys.com](mailto:fmclean@cdcnac.aspensys.com) via the Internet) at the CDC National  
AIDS Clearinghouse; include the title, dates, site, sponsoring  
agency, contact information, registration fee, and topics to be  
discussed at the conference.

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:17-SEP-1996 12:05:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9L27WRT1C0007KL@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Tue,  
17 Sep 1996 12:04:50 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9L27UR78000082C@PMDF.EOP.GOV> for  
levi\_j@a1.eop.gov; Tue, 17 Sep 1996 12:04:47 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9L25CTOAU00007Y@STORM.EOP.GOV> for  
levi\_j@a1.eop.gov; Tue, 17 Sep 1996 12:02:46 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id MAA11096; Tue,  
17 Sep 1996 12:04:49 -0400

Errors-to: [shelly\\_olim\\_at\\_aspenpo@smtpinet.aspensys.com](mailto:shelly_olim_at_aspenpo@smtpinet.aspensys.com)

Precedence: bulk

Originator: [aidsnews@cdcnac.aspensys.com](mailto:aidsnews@cdcnac.aspensys.com)

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:17-SEP-1996 10:17:29.90

SUBJECT: Hot issues

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)

READ:17-SEP-1996 10:22:05.65

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)

READ:17-SEP-1996 12:04:47.52

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)

READ:23-SEP-1996 09:25:13.68

TO: Dennis Burke ( BURKE\_D ) (OPD)

READ:20-SEP-1996 13:17:25.44

TO: Diane Regas ( REGAS\_D ) (OPD)

READ:17-SEP-1996 11:32:20.70

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:17-SEP-1996 10:54:41.43

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)

READ:17-SEP-1996 11:48:26.45

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)

READ:17-SEP-1996 17:40:27.69

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)

READ:17-SEP-1996 11:55:22.99

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:17-SEP-1996 10:19:17.04

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

READ:17-SEP-1996 10:22:44.57

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)

READ:17-SEP-1996 10:30:59.64

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)

READ:17-SEP-1996 10:43:04.35

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)

READ:17-SEP-1996 10:22:18.51

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)

READ:17-SEP-1996 12:41:27.76

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:17-SEP-1996 11:35:42.21

TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S ) (OPD)  
READ:18-SEP-1996 15:37:13.44

TEXT:

The President will travel to NYC, Philadelphia, Pittsburgh, and New Hampshire later this month. Please let me know before Friday if there are issues he should be aware of on these trips. If the issues you raise are not covered by the cabinet agencies, then you will need to prepare a SHORT update on them. I'll let you know later this week whether cabinet affairs is already doing the issues that you raise. If you'd like to see any cab affairs write-ups, please let me know that too so I can get them to you for your review before they go to staff secretary. THanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:17-SEP-1996 10:19:35.61

SUBJECT: RE: Hot issues

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)

READ:17-SEP-1996 11:31:33.72

CC: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:17-SEP-1996 13:08:33.20

TEXT:

AIDS funding is always an issue in these places -- especially for the AIDS drug assistance program -- he should be able to take credit for all the increases (and prepared for responding to questions about needing more). We can spit this out quickly if HHS has not included them.

# Withdrawal/Redaction Marker

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                                                                                                 | DATE       | RESTRICTION            |
|--------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| 001. email               | From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt.<br>Request for Levi, Jeffrey W [Personally Identifiable Information]<br>[partial] (1 page) | 09/17/1996 | b(7)(C), b(7)(F), b(6) |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F  
jn432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES RECEIPT)

CREATOR: Mail Link Monitor ( MAILMGT ) (SYS)

CREATION DATE/TIME:17-SEP-1996 10:27:16.46

SUBJECT: CONFIRMATION: APPT. REQUEST FOR LEVI, JEFFREY W

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:17-SEP-1996 10:39:48.67

TEXT:

FROM: WAVES OPERATIONS CENTER - ACO: (b)(6), (b)(7)c, (b)(7)f

Date: 09-17-1996

Time: 10:22:26

This message serves as confirmation of an appointment for the visitors listed below.

Appointment With: LEVI, JEFFREY W

Appointment Date: 9/17/96

Appointment Time: 11:00:00 AM

Appointment Room: 211

Appointment Building: OEOB

Appointment Requested by: LEVI JEFFREY

Phone Number of Requestor: 21090

Comments:

WAVES APPOINTMENT NUMBER: U43361

If you have any questions regarding this appointment, please call the WAVES Center at 456-6742 and have the appointment number listed above available to the Access Control Officer answering your call.

\*\*\*\*\*

TOTAL NUMBER OF NAMES SUBMITTED FOR ENTRY : 1

TOTAL NUMBER OF NAMES OF CLEARED FOR ENTRY: 1

\*\*\*\*\*

SANVILLE, U

(b)(6)

[001]

# Withdrawal/Redaction Marker

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                              | DATE       | RESTRICTION |
|--------------------------|--------------------------------------------------------------------------------------------|------------|-------------|
| 002. email               | From: Jeffrey Levi, To: Remote Addressee, Re: At Last... [personal]<br>[partial] (2 pages) | 09/17/1996 | b(6)        |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F  
jn432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:17-SEP-1996 17:41:38.96

SUBJECT: At last...

TO: Remote Addressee ( 75051.3374@compuserve.com@INET@EOPMRX )  
READ:NOT READ

TEXT:

So we finally had our meeting today with HHS (Carol Williams) about the grandparents project. I think it went well and we are moving forward with planning an event for October. We can't guarantee that we'll have FLOTUS there, but we are planning as though...which will force the agencies to move forward.

We are casting this as an event that will honor those who have personally or professionally confronted this issue...so Jane will be contacting you about names, etc. (in addition to yours).

As to substance:

(1) Under the Abandoned Infants Program, HHS will be awarding about \$11 million shortly in grants that focus on permanency planning; this program has a particular focus on AIDS orphans.

(2) The Abandoned Infants Resource Center in Berkeley (a federal contractor) will be directed to do some special focus work on these issues.

(3) An ABA legal resource center under contract to HHS will be directed to develop a technical assistance package for the field regarding options with regard to permanency planning, co-guardianship, etc. for HIV-infected parents. This would be for service providers (how to get through the bureaucratic maze) and for policy people (advocates, state legislators) regarding model regulations/legislation that could be passed at the state level.

(4) We will work with HRSA to see what linkage can be done with the Ryan White programs -- including putting something in the FY 1997 RFP for the SPNS (Special Projects of National Significance) program that would encourage applications for demonstration programs for services around these issues.

It's a start -- having an event will force some decisions (even if we end up without FLOTUS -- though if she is here at the right time, I think Jen wants to go forward with it).

(Obviously, the event idea is still under wraps.)

It was a VERY harmonious meeting; everyone was eager to move forward. I think we have finally convinced our colleagues at DPC we are not using this as a backdoor attempt to change child welfare policy.

So...you have gotten something moving...we have not forgotten you...and poor Jane is now going to experience the joys of planning a White House event!

Hope things are going well;

(b)(6)

(b)(6)

[002]

(b)(6)

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:17-SEP-1996 13:19:34.25

SUBJECT: RE: Nancy-Ann Meetings and other items

TO: Wm G. White ( Wm G. White@EOP@LNGTWY@EOPMRX )  
READ:NOT READ

TEXT:  
so do you have new software for email -- this comes through  
differently now.  
also I just faxed you something re the immigration bill

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:17-SEP-1996 15:25:37.85

SUBJECT: RE: subscriptions

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:17-SEP-1996 17:07:48.49

TEXT:

I would suggest --

The journal "AIDS" and an AIDS policy journal (the precise name escapes me --  
I'll look for it on the net.)

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:17-SEP-1996 13:44:39.29

SUBJECT: subscriptions

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:17-SEP-1996 13:52:30.76

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)  
READ:17-SEP-1996 15:23:18.47

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:17-SEP-1996 14:03:23.33

TO: Richard Sorian ( SORIAN\_R ) (OPD)  
READ:NOT READ

TEXT:  
here we go again.  
Ashley has lost the subscription list as have I; she promises we  
can get everything with end of the year money -- please get me  
your ideas asap.  
thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:18-SEP-1996 10:59:35.83

SUBJECT: daily news

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:18-SEP-1996 12:24:55.26

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)  
READ:19-SEP-1996 13:46:09.30

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:20-SEP-1996 10:06:05.94

TEXT:

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:18-SEP-1996 10:22:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 09/18/96

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

AIDS Daily Summary  
September 18, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*  
"More Germs Elude Drugs"  
"Three TV Stations to Run Condom Ads"  
"Researcher Cites Genetic Factor in HIV Resistance"  
"Denver Extends Health Coverage to Partners of Gay City Employees"  
"Brudnoy, Feeling Healthier, Launches AIDS Research Drive"  
"New Needs of Society Bring Back a Medical Dinosaur: House Calls"  
"AIDS Cases Seen Decreasing in France"

"6,800 Sri Lankans Suspected to be AIDS Carriers"

"Flirting With Suicide"

"No End of Plagues"

\*\*\*\*\*

"More Germs Elude Drugs"

USA Today (09/18/96) P. 1D; Manning, Anita

The rise of drug-resistant microbes is making common infections more difficult to treat, scientists said at a recent meeting of the American Society for Microbiology. For example, the increasing use of antifungal drugs, especially for patients with AIDS or those receiving chemotherapy, has led to resistance. Development of new drugs to treat fungal infections is underway, but will take a long time.

"Three TV Stations to Run Condom Ads"

Washington Times (09/18/96) P. A11

Three NBC affiliate television stations, in Houston, Seattle, and Chico, Calif., will run paid advertising for condoms, marking the first time that such commercials have been accepted by a major network station. The 60-second ad has been run by MTV and Comedy Central for a year, but was rejected by the major networks and about 40 TV stations.

"Researcher Cites Genetic Factor in HIV Resistance"

Boston Globe (09/17/96) P. A5

Genetic protection from HIV infection is more common in Caucasians than in people of African descent, a researcher reported at the annual meeting of the Institute of Human Virology last week. Steven O'Brien of the National Cancer Institute studied more than 1,900 American men and women who have been exposed to HIV repeatedly and have either not become infected or have been HIV-positive for a long time. The gene, CKR-5, slows progression of HIV infection and allows individuals to live an average of two years longer than infected individuals without the gene. People who inherit the gene from both parents have absolute protection from HIV, while the protection is partial in people who inherit the gene from one parent. No individuals of African descent have been identified as having any genetic protection.

"Denver Extends Health Coverage to Partners of Gay City Employees"

New York Times (09/18/97) P. A17; Brooke, James

Gay partners of workers employed by the city of Denver will receive health insurance coverage under an ordinance to be signed today. The decision is part of a trend in companies and local governments to offer health benefits to gay partners of employees. Lantz Trantham, a businessman who opposed the ordinance, called it "financially irresponsible, not just with AIDS, but with the multitude of sexually transmitted diseases." An atmosphere of tolerance exists in the city, where a record 10,000 people participated in the annual AIDS walk last week. The event raised \$1.2 million for state AIDS services.

"Brudnoy, Feeling Healthier, Launches AIDS Research Drive"  
Boston Globe (09/17/96) P. B8; Knox, Richard A.

Boston radio talk show host David Brudnoy, who nearly died of AIDS two years ago, is feeling healthier lately due to a new combination of drugs. He launched a campaign for AIDS research Tuesday, aiming to raise \$10 million for research at Massachusetts General and Brigham and Women's hospitals. The funds would boost the AIDS clinical research budget at the hospitals by about 40 percent. Brudnoy explains that he created the AIDS research fund to help "carry us from where we are now--optimism, but guarded--to optimism with confidence."

"New Needs of Society Bring Back a Medical Dinosaur: House Calls"  
New York Times (09/18/96) P. C11; Gilbert, Susan

The demand for doctors to make house calls is rising, due to a growing number of people--including the elderly, AIDS patients, and those disabled by violence--who want to stay home for care. At an American Medical Association symposium last week, it was reported that the number of house calls charged to Medicare rose from 37 million in 1988 to 218 million in 1994. However, only about three million of the visits each year are made by physicians; nurses, social workers, and home health aides make the rest. Currently, new tools--including a video telephone system and digital stethoscopes and blood pressure monitors--are being developed to help doctors recognize which patients need to be visited in person.

"AIDS Cases Seen Decreasing in France"  
Reuters (09/17/96)

The number of full-blown AIDS cases in France decreased in the first half of 1996, leading officials to expect a continuing annual decline. The health ministry reported Tuesday that 2,507 new AIDS cases were reported between January and June, which would amount to 5,014 cases for the year if the trend continues. Last year, 5,469 cases were reported, down from 5,789 in 1994.

"6,800 Sri Lankans Suspected to be AIDS Carriers"  
Xinhua News Agency (09/18/96)

Health officials in Sri Lanka say that an estimated 6,800 people in the country have AIDS. The first AIDS case in Sri Lanka was identified in 1986 in a man who became infected in London. By 2005, more than 80,000 Sri Lankans are expected to have with HIV. The economic impact of each AIDS case is expected to reach \$19,000.

"Flirting With Suicide"  
New York Times Magazine (09/15/96) P. 39; Green, Jesse

Since 1981, HIV prevention campaigns targeted at the gay community have contained the same message--that "a condom every time" is the only way to be protected. Although the average number of unsafe sex contacts for gay men in New York City declined from more than 11 per year in 1980 to one per year in 1991, many gay men are no longer heeding safer sex warnings. As it became known that AIDS would not be cured quickly, and that

safety precautions could not be temporary, the gay community began giving up the battle. By 1991, men who had been safe for at least six years were becoming less cautious, and men who had never been safe saw it as futile to start. By 1990, the weaknesses in AIDS education became apparent. Black and Latino men had not been reached, and young homosexuals were also at high risk. HIV rates among older, white, gay men who had heard the message even started rising. Berkeley psychologist Walt Odets criticizes HIV prevention campaigns targeted at gay men for being coercive and dishonest. He advocates messages that include information about relative risk and that encourage communication between partners to determine risk.

"No End of Plagues"

Economist--Sub-Saharan Africa Survey (09/07/96) Vol. 340, No. 7982, P. 15

Africa faces several disease threats, but the most serious is that of AIDS. The disease was initially thought to affect only the white homosexual community, and even as it spread to the general population, it was not considered a serious problem. Now, however, the threat is recognized and complacency is gone. The World Health Organization estimates that about 24 million people in sub-Saharan Africa will be HIV-positive by the year 2000. AIDS is spreading quickly throughout the region, and young military men--who spend a lot of time traveling--are especially vulnerable to HIV. Still, anti-AIDS drugs, including older drugs like AZT, are not affordable in Africa. To combat the disease, South Africa has taken several measures, including implementing sexual education programs for young people; providing treatment for sexually transmitted diseases; promoting safer sex on billboards, taxis, music tapes, and calendars; and increasing condom distribution.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:18-SEP-1996 10:24:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9MCY84IV4000GYD@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Wed,  
18 Sep 1996 10:23:11 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9MCY29XU800082Q@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Wed, 18 Sep 1996 10:23:03 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9MCVETMAA00007Y@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Wed, 18 Sep 1996 10:20:54 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA07492; Wed,  
18 Sep 1996 10:22:51 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:18-SEP-1996 16:42:59.65

SUBJECT: RE: AIDS MEMORIASL GROVE

TO: Richard Socarides ( SOCARIDES\_R ) (WHO)

READ:18-SEP-1996 16:50:09.60

TEXT:

I'll try...but I have a number of meetings during the day.  
late afternoon is much better for me.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: SYSTEM@MRGATE@CD

CREATION DATE/TIME:18-SEP-1996 14:34:00.00

SUBJECT: SENT #671226 to 9-1-212-673-6128. 5 pages

TO: LEVI\_J@A1@CD@CD

READ:18-SEP-1996 14:38:44.93

TEXT:

FACSIMILE ACTIVITY REPORT

SENT STATUS: Sent successfully

Recipients FAX number: 9-1-212-673-6128

FAX Completion time: 18-SEP-96 14:27

Number of pages: 5

Transaction number: 671226

(Please call Client Services at 395-7370 for further assistance)

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-SEP-1996 14:35:00.00

ATT BODYPART TYPE:D

TEXT:

VMSmail To information: MRGATE::CD::A1::LEVI\_J

Sender's personal name: System Manager

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:18-SEP-1996 09:47:57.50

SUBJECT: RE: NIH thank yous

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:18-SEP-1996 09:48:10.14

TEXT:

I'll let Toby know.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard Socarides (SOCARIDES\_R) (WHO)

CREATION DATE/TIME:18-SEP-1996 16:40:55.54

SUBJECT: AIDS MEMORIASL GROVE

TO: Jeffrey Levi (LEVI\_J) (WHO)

READ:18-SEP-1996 16:41:57.48

TEXT:

THEY are coming to see me tomorrow. PLEASE come! You owe me this.  
I'll let you know when.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Dorothy K. Craft ( CRAFT\_D ) (OPD)

CREATION DATE/TIME:18-SEP-1996 11:56:51.98

SUBJECT: FYI and Any idea?

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:18-SEP-1996 13:36:46.25

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-SEP-1996 11:26:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Dorothy K. Craft

ATT SUBJECT: also re: call

ATT TO: Patsy Fleming ( FLEMING\_P )

ATT CC: Carmena Parris ( PARRIS\_C )

TEXT:

if you'd like scott on call, please have him call into you or  
share w/me his phone number. thanks.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:18-SEP-1996 11:07:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Dorothy K. Craft

ATT SUBJECT: Conference Call TODAY

ATT TO: Diana M. Fortuna ( FORTUNA\_D )

ATT TO: Patsy Fleming ( FLEMING\_P )

ATT TO: Carmena Parris ( PARRIS\_C )

ATT TO: Christopher C. Jennings ( JENNINGS\_C )

ATT TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S )

TEXT:

The Conference Call to discuss the HIV/AIDS Welfare letter will be  
from 4:15 to 4:30 today. I will conference everyone in.

Again, this call is to discuss some errors within the letter.

Thanks.

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

CREATION DATE/TIME:18-SEP-1996 13:43:52.26

SUBJECT: ROZ / new address

TO: Janet B. Abrams ( ABRAMS\_J ) (VPO)  
READ:18-SEP-1996 14:03:15.24

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:18-SEP-1996 18:47:45.31

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:23-SEP-1996 10:23:13.05

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:20-SEP-1996 18:26:33.24

TO: Pamela Cicetti ( CICETTI\_P ) (WHO)  
READ:18-SEP-1996 13:48:05.55

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:19-SEP-1996 10:52:33.82

TO: Deborah L. Fine ( FINE\_D ) (OPD)  
READ:18-SEP-1996 13:43:56.93

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:18-SEP-1996 13:44:02.96

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ:22-SEP-1996 23:46:05.78

TO: Dorothy K. Craft ( CRAFT\_D ) (OPD)  
READ:18-SEP-1996 14:08:34.31

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:18-SEP-1996 14:28:08.66

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:18-SEP-1996 13:44:10.24

TO: Cathy R. Mays ( MAYS\_C ) (OPD)  
READ:18-SEP-1996 13:47:05.85

TO: Carol H. Rasco ( RASCO\_C ) (WHO)  
READ:18-SEP-1996 18:04:35.90

TO: Bruce N. Reed ( REED\_B ) (WHO)  
READ:18-SEP-1996 13:44:59.76

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:18-SEP-1996 13:44:06.80

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:18-SEP-1996 13:57:24.07

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:18-SEP-1996 14:01:17.26

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:18-SEP-1996 14:02:31.46

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:18-SEP-1996 16:56:35.79

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:18-SEP-1996 18:38:48.46

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:18-SEP-1996 13:46:17.98

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:18-SEP-1996 18:16:08.01

TEXT:  
just an fyi to all and I'll update this on that staff roster:  
Roz's new address:  
2400 Riverfront Drive  
#1627  
Little Rock, AR 72202  
(501) 614-7792, home  
(501) 686-2220, pager

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:18-SEP-1996 14:16:16.68

SUBJECT: PD ADVISORY COMMISSION ON CONSUMER PROTECTION AND QUALITY I

TO: FAX (9-1-212-673-6128,Tim Sweeney) ( TLXA1MAIL \_\F:9-1-212-673-6128\C:Tim Sweeney\\ )  
READ:NOT READ

TEXT:

THE WHITE HOUSE  
Office of the Press Secretary

---

For Immediate Release

September 5, 1996

EXECUTIVE ORDER

-----

ADVISORY COMMISSION ON CONSUMER PROTECTION  
AND QUALITY IN THE HEALTH CARE INDUSTRY

By the authority vested in me as President by the Constitution and the laws of the United States of America, including the Federal Advisory Committee Act, as amended (5 U.S.C. App.), it is hereby ordered as follows:

Section 1. Establishment. (a) There is established the Advisory Commission on Consumer Protection and Quality in the Health Care Industry (the "Commission"). The Commission shall be composed of not more than 20 members to be appointed by the President. The members will be consumers, institutional health care providers, health care professionals, other health care workers, health care insurers, health care purchasers, State and local government representatives, and experts in health care quality, financing, and administration.

(b) The Secretary of Health and Human Services and the Secretary of Labor shall serve as Co-Chairs of the Commission. The Co-Chairs shall report through the Vice President to the President.

Sec. 2. Functions. (a) The Commission shall advise the President on changes occurring in the health care system and recommend such measures as may be necessary to promote and assure health care quality and value, and protect consumers and workers in the health care system. In particular, the Commission shall:

(1) Review the available data in the area of consumer information and protections for those enrolled in health care plans and make such recommendations as may be necessary for improvements;

(2) Review existing and planned work that defines, measures, and promotes quality of health care, and help build further consensus on approaches to assure and promote quality of care in a changing delivery system; and

(3) Collect and evaluate data on changes in availability of treatment and services, and make such recommendations as may be necessary for improvements.

(b) For the purpose of carrying out its functions, the Commission may hold hearings, establish subcommittees, and convene and act at such times and places as the Commission may find advisable.

more

(OVER)

2

Sec. 3. Reports. The Commission shall make a preliminary report to the President by September 30, 1997. A final report shall be submitted to the President 18 months after the Commission's first meeting.

Sec. 4. Administration. (a) To the extent permitted by law, the heads of executive departments and agencies, and independent agencies (collectively "agencies") shall provide the Commission, upon request, with such information as it may require for the purposes of carrying out its functions.

(b) Members of the Commission may receive compensation for their work on the Commission not to exceed the daily rate specified for Level IV of the Executive Schedule (5 U.S.C. 5315). While engaged in the work of the Commission, members appointed from among private citizens of the United States may be allowed travel expenses, including per diem in lieu of subsistence, as authorized by law for persons serving intermittently in the Government service (5 U.S.C. 5701-5707) to the extent funds are available for such purposes.

(c) To the extent permitted by law and subject to the availability of appropriations, the Department of Health and Human Services shall provide the Commission with administrative services, funds, facilities, staff, and other support services necessary for the performance of the Commission's functions. The Secretary of Health and Human Services shall perform the administrative functions of the President under the Federal Advisory Committee Act, as amended (5 U.S.C. App.), with respect to the Commission.

Sec. 5. General Provision. The Commission shall terminate 30 days after submitting its final report, but not later than 2 years from the date of this order, unless extended by the President.

WILLIAM J. CLINTON

THE WHITE HOUSE,  
September 5, 1996.

# # #

# Withdrawal/Redaction Marker

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                               | DATE       | RESTRICTION |
|--------------------------|---------------------------------------------------------------------------------------------|------------|-------------|
| 003. email               | From: Jeffrey Levi, To: Patsy Fleming, Re: Jumping the Gun<br>[personal] [partial] (1 page) | 09/18/1996 | b(6)        |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F  
jn432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:18-SEP-1996 15:21:53.27

SUBJECT: jumping the gun

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:18-SEP-1996 18:16:31.87

TEXT:

I may have jumped the gun in talking with Sherry a little about the Advisory Council this afternoon...I told her I wanted her to be on a conference call tomorrow with a group from the services committee...the meeting with her and Daniel had not been set yet and I probably should have waited. I told her you would be describing in detail what you had in mind for her to be doing...it's clear she wants to be doing writing not other work...so (b)(6)

(b)(6) this may not be an easy discussion for you.

[003]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:18-SEP-1996 09:40:56.92

SUBJECT: NIH thank yous

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:18-SEP-1996 09:45:32.89

TEXT:

Attached is proposed lanaguage for thank yous to Bill Paul and Varmus from Toby.

I think they're fine. Ok by you?

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:17-SEP-1996 18:26:00.00

ATT BODYPART TYPE:E

ATT CREATOR: Toby Donenfeld

ATT SUBJECT: Thank you for Bill Paul

ATT TO: SANVILLE\_U ( SANVILLE\_U@A1@CD )

ATT TO: LEVI\_J ( LEVI\_J@A1@CD )

TEXT:

Message Creation Date was at 17-SEP-1996 18:26:00

How's this? Same letter for Varmus minus the second paragraph?

September 17, 1996

Dr. Bill Paul  
Director, Office of AIDS Research  
National Institutes of Health  
Building 31 4CO2  
9000 Rockville Pike  
Bethesda, MD 20892

Dear Dr. Paul:

I wanted to thank you for the briefing you provided to me on Friday, August 2. I appreciated hearing your report from the Vancouver conference and the implications of the new advances in science. I also appreciated receiving the Federal Biomedical Research Plan and Budget and the general update on the progress in the development of vaccines, therapeutics and microbicides.

I also wanted to thank you for personally guiding the development of the

first-ever Federal Biomedical Research Plan and Budget for HIV and AIDS. The care and attention provided by you and your staff was instrumental in the successful development of the plan. I appreciate your efforts.

Again, thank you for coming in to meet with me.

Sincerely,

Al Gore

AG/td

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:18-SEP-1996 09:45:21.38

SUBJECT: RE: NIH thank yous

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:18-SEP-1996 09:47:35.02

TEXT:

yes

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:18-SEP-1996 10:23:00.00

SUBJECT: CDC AIDS Daily Summary 09/18/96

TO: levi\_j ( levi\_j@A1@CD ) (WHO)

READ:18-SEP-1996 10:59:19.49

TEXT:

AIDS Daily Summary  
September 18, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"More Germs Elude Drugs"

"Three TV Stations to Run Condom Ads"

"Researcher Cites Genetic Factor in HIV Resistance"

"Denver Extends Health Coverage to Partners of Gay City Employees"

"Brudnoy, Feeling Healthier, Launches AIDS Research Drive"

"New Needs of Society Bring Back a Medical Dinosaur: House Calls"

"AIDS Cases Seen Decreasing in France"

"6,800 Sri Lankans Suspected to be AIDS Carriers"

"Flirting With Suicide"

"No End of Plagues"

\*\*\*\*\*

"More Germs Elude Drugs"

USA Today (09/18/96) P. 1D; Manning, Anita

The rise of drug-resistant microbes is making common infections more difficult to treat, scientists said at a recent meeting of the American Society for Microbiology. For example, the increasing use of antifungal drugs, especially for patients with AIDS or those receiving chemotherapy, has led to resistance. Development of new drugs to treat fungal infections is underway, but will take a long time.

"Three TV Stations to Run Condom Ads"

Washington Times (09/18/96) P. A11

Three NBC affiliate television stations, in Houston, Seattle, and Chico, Calif., will run paid advertising for

condoms, marking the first time that such commercials have been accepted by a major network station. The 60-second ad has been run by MTV and Comedy Central for a year, but was rejected by the major networks and about 40 TV stations.

"Researcher Cites Genetic Factor in HIV Resistance"

Boston Globe (09/17/96) P. A5

Genetic protection from HIV infection is more common in Caucasians than in people of African descent, a researcher reported at the annual meeting of the Institute of Human Virology last week. Steven O'Brien of the National Cancer Institute studied more than 1,900 American men and women who have been exposed to HIV repeatedly and have either not become infected or have been HIV-positive for a long time. The gene, CKR-5, slows progression of HIV infection and allows individuals to live an average of two years longer than infected individuals without the gene. People who inherit the gene from both parents have absolute protection from HIV, while the protection is partial in people who inherit the gene from one parent. No individuals of African descent have been identified as having any genetic protection.

"Denver Extends Health Coverage to Partners of Gay City Employees"

New York Times (09/18/97) P. A17; Brooke, James

Gay partners of workers employed by the city of Denver will receive health insurance coverage under an ordinance to be signed today. The decision is part of a trend in companies and local governments to offer health benefits to gay partners of employees. Lantz Trantham, a businessman who opposed the ordinance, called it "financially irresponsible, not just with AIDS, but with the multitude of sexually transmitted diseases." An atmosphere of tolerance exists in the city, where a record 10,000 people participated in the annual AIDS walk last week. The event raised \$1.2 million for state AIDS services.

"Brudnoy, Feeling Healthier, Launches AIDS Research Drive"

Boston Globe (09/17/96) P. B8; Knox, Richard A.

Boston radio talk show host David Brudnoy, who nearly died of AIDS two years ago, is feeling healthier lately due to a new combination of drugs. He launched a campaign for AIDS research Tuesday, aiming to raise \$10 million for research at Massachusetts General and Brigham and Women's hospitals. The funds would boost the AIDS clinical research budget at the hospitals by about 40 percent. Brudnoy explains that he created the AIDS research fund to help "carry us from where we are now--optimism, but guarded--to optimism with confidence."

"New Needs of Society Bring Back a Medical Dinosaur: House Calls"

New York Times (09/18/96) P. C11; Gilbert, Susan

The demand for doctors to make house calls is rising, due to a growing number of people--including the elderly, AIDS patients, and those disabled by violence--who want to stay home for care. At an American Medical Association symposium last week, it was reported that the number of house calls charged to Medicare rose

from 37 million in 1988 to 218 million in 1994. However, only about three million of the visits each year are made by physicians; nurses, social workers, and home health aides make the rest. Currently, new tools--including a video telephone system and digital stethoscopes and blood pressure monitors--are being developed to help doctors recognize which patients need to be visited in person.

#### "AIDS Cases Seen Decreasing in France"

Reuters (09/17/96)

The number of full-blown AIDS cases in France decreased in the first half of 1996, leading officials to expect a continuing annual decline. The health ministry reported Tuesday that 2,507 new AIDS cases were reported between January and June, which would amount to 5,014 cases for the year if the trend continues. Last year, 5,469 cases were reported, down from 5,789 in 1994.

#### "6,800 Sri Lankans Suspected to be AIDS Carriers"

Xinhua News Agency (09/18/96)

Health officials in Sri Lanka say that an estimated 6,800 people in the country have AIDS. The first AIDS case in Sri Lanka was identified in 1986 in a man who became infected in London. By 2005, more than 80,000 Sri Lankans are expected to have with HIV. The economic impact of each AIDS case is expected to reach \$19,000.

#### "Flirting With Suicide"

New York Times Magazine (09/15/96) P. 39; Green, Jesse

Since 1981, HIV prevention campaigns targeted at the gay community have contained the same message--that "a condom every time" is the only way to be protected. Although the average number of unsafe sex contacts for gay men in New York City declined from more than 11 per year in 1980 to one per year in 1991, many gay men are no longer heeding safer sex warnings. As it became known that AIDS would not be cured quickly, and that safety precautions could not be temporary, the gay community began giving up the battle. By 1991, men who had been safe for at least six years were becoming less cautious, and men who had never been safe saw it as futile to start. By 1990, the weaknesses in AIDS education became apparent. Black and Latino men had not been reached, and young homosexuals were also at high risk. HIV rates among older, white, gay men who had heard the message even started rising. Berkeley psychologist Walt Odets criticizes HIV prevention campaigns targeted at gay men for being coercive and dishonest. He advocates messages that include information about relative risk and that encourage communication between partners to determine risk.

#### "No End of Plagues"

Economist--Sub-Saharan Africa Survey (09/07/96) Vol. 340, No. 7982, P. 15

Africa faces several disease threats, but the most serious is that of AIDS. The disease was initially thought to affect only the white homosexual community, and even as it spread to the

general population, it was not considered a serious problem. Now, however, the threat is recognized and complacency is gone. The World Health Organization estimates that about 24 million people in sub-Saharan Africa will be HIV-positive by the year 2000. AIDS is spreading quickly throughout the region, and young military men--who spend a lot of time traveling--are especially vulnerable to HIV. Still, anti-AIDS drugs, including older drugs like AZT, are not affordable in Africa. To combat the disease, South Africa has taken several measures, including implementing sexual education programs for young people; providing treatment for sexually transmitted diseases; promoting safer sex on billboards, taxis, music tapes, and calendars; and increasing condom distribution.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:18-SEP-1996 10:24:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9MCY84IV4000GYD@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Wed,  
18 Sep 1996 10:23:11 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9MCY29XU800082Q@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Wed, 18 Sep 1996 10:23:03 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9MCVETMAA00007Y@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Wed, 18 Sep 1996 10:20:54 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA07492; Wed,  
18 Sep 1996 10:22:51 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jennifer L. Klein ( KLEIN\_J ) (OPD)

CREATION DATE/TIME:18-SEP-1996 15:58:25.70

SUBJECT: Immigration

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:18-SEP-1996 16:41:48.96

TEXT:

I spoke with Tim about the immigration issue. If you need help pushing it let me know.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 11:22:32.50

SUBJECT: quilt meeting

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:19-SEP-1996 12:02:42.82

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-SEP-1996 11:00:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Richard Socarides

ATT SUBJECT: RE: AIDS Quilt weekend

ATT TO: Jeffrey Levi ( LEVI\_J )

TEXT:

166 OEOB.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 10:59:59.09

SUBJECT: fyi

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:19-SEP-1996 11:02:47.38

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-SEP-1996 10:53:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Jeremy D. Benami

ATT SUBJECT: RE: AIDS Quilt weekend

ATT TO: Richard Socarides ( SOCARIDES\_R )

ATT CC: Jeffrey Levi ( LEVI\_J )

TEXT:

I can't make it.

sorry.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard Socarides (SOCARIDES\_R) (WHO)

CREATION DATE/TIME:19-SEP-1996 11:21:52.84

SUBJECT: RE: AIDS Quilt weekend

TO: Jeffrey Levi (LEVI\_J) (WHO)

READ:19-SEP-1996 11:22:37.53

TEXT:

166 OEOB.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Wm G. White@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:19-SEP-1996 14:45:00.00

SUBJECT: Ryan White Numbers

TO: LEVI\_J ( LEVI\_J@A1@CD ) (WHO)

READ:19-SEP-1996 14:51:07.75

TEXT:

Message Creation Date was at 19-SEP-1996 14:45:00

To meet the POTUS request for Ryan White, we need the following increases:

Title I -- +\$23.243 million

Title II Regular Grant (non-ADAP Set-Aside) -- +\$17.107 million

Title IIIb -- +\$2.650 million

All other titles are either at or above the POTUS request.

# Withdrawal/Redaction Marker

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                                                                                                      | DATE       | RESTRICTION            |
|--------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------------------|
| 004. email               | From: Mail Link Monitor, To: Jeffrey Levi, Re: Confirmation: Appt.<br>Request for Socarides, Richard C [Personally Identifiable Information]<br>[partial] (1 page) | 09/19/1996 | b(7)(C), b(7)(F), b(6) |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F

jn432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES RECEIPT)

CREATOR: Mail Link Monitor ( MAILMGT ) (SYS)

CREATION DATE/TIME:19-SEP-1996 11:34:31.25

SUBJECT: CONFIRMATION: APPT. REQUEST FOR SOCARIDES, RICHARD C

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:19-SEP-1996 11:45:51.37

TEXT:

FROM: WAVES OPERATIONS CENTER - ACO:

(b)(6), (b)(7)c, (b)(7)f

Date: 09-19-1996

Time: 11:32:39

This message serves as confirmation of an appointment for the visitors listed below.

Appointment With: SOCARIDES, RICHARD C

Appointment Date: 9/20/96

Appointment Time: 10:45:00 AM

Appointment Room: 166

Appointment Building: OEOB

Appointment Requested by: LEVI JEFFREY

Phone Number of Requestor: 21090

Comments:

WAVES APPOINTMENT NUMBER: U44363

If you have any questions regarding this appointment, please call the WAVES Center at 456-6742 and have the appointment number listed above available to the Access Control Officer answering your call.

\*\*\*\*\*

TOTAL NUMBER OF NAMES SUBMITTED FOR ENTRY : 2

TOTAL NUMBER OF NAMES OF CLEARED FOR ENTRY: 2

\*\*\*\*\*

MONTOYA, DANIEL

SORIAN, RICHARD

(b)(6)

[004]

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:19-SEP-1996 10:16:00.00

SUBJECT: CDC AIDS Daily Summary 09/19/96

TO: levi\_j ( levi\_j@A1@CD ) (WHO)

READ:19-SEP-1996 10:28:50.16

TEXT:

AIDS Daily Summary  
September 19, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"Virus Chase: Five Teams Pursue Herpes Drug"

"Boxer Morrison Plans Comeback"

"Ontario to Promote Hepatitis B Shots"

"No-Consent Tests Near on Humans"

"Researchers Develop Cream to Prevent Herpes"

"Three Drug Firm Executives Held in Japan AIDS Case"

"AIDS Seminar to Be Held in Nicaragua"

"Condom Day to Be Observed in East Nepal"

"Discarded Needles Spur Call for Reviewing Exchange Program"

"The Return of an Ancient Killer"

\*\*\*\*\*

"Virus Chase: Five Teams Pursue Herpes Drug"

Wall Street Journal (09/19/96) P. B6; Bishop, Jerry E.

The discovery of a weakness in a herpes virus called cytomegalovirus (CMV), which causes blindness in AIDS patients, has resulted in a race to develop drugs against CMV and other herpes viruses. Research teams at SmithKline Beecham, Boehringer Ingelheim, and Monsanto reported the finding simultaneously and are racing to develop drugs that take advantage of it. Scientists at Agouron Pharmaceuticals and Arris Pharmaceutical are also following the same strategy to rush drug development. The research follows the same path that was used to develop protease inhibitors--finding a drug that will block a protein the virus needs to replicate.

"Boxer Morrison Plans Comeback"

USA Today (09/19/96) P. 1C; Saraceno, Jon

Tommy Morrison, the heavyweight fighter who retired from the sport eight months ago after learning that he was infected with HIV, is planning to announce that he will return to the ring. Although the leading boxing-rich states require fighters to test negative for HIV, Morrison could potentially fight in about six states or overseas--or challenge the legality of the requirement. The Nevada boxing commission suspended Morrison because he tested positive, and the executive director of that commission said he would "expect all states that have boxing commissions to honor our suspension."

#### "Ontario to Promote Hepatitis B Shots"

Toronto Globe and Mail (09/18/96) P. A7; Immen, Wallace

High school students in Ontario would be vaccinated for hepatitis B under a voluntary program to be announced this week. The virus, which is spread through blood or sexual contact, can cause liver damage. The risk for high school students has increased due to the trend of body piercing and tattooing. Hepatitis B is approximately 100 times more infectious than AIDS, according to the Canadian Liver Foundation.

#### "No-Consent Tests Near on Humans"

Chicago Tribune (09/18/96) P. 1-1; Schreuder, Cindy; Hutchcraft, Chuck

Chicago's Cook County Hospital is preparing to test an experimental blood substitute that would be given to trauma patients unable to give their consent. The substitute offers the critical time-saving advantage of not having to be matched to a patient's blood type. The testing in Chicago is part of a national study that is on hold until the federal government approves rules that will allow promising experimental therapies to be given to trauma patients without their consent. Blood substitutes, which can be stored much longer than donated blood, could be also used to meet demands when the blood supply is low. Although researchers have been trying to find a substitute for blood for hundreds of years, its importance was highlighted after some people contracted HIV via contaminated blood transfusions.

#### "Researchers Develop Cream to Prevent Herpes"

Reuters (09/18/96)

A cream to prevent genital herpes, and possibly other sexually transmitted diseases, has been developed from human bile acid, researchers at Cincinnati's Children's Hospital Medical Center reported. The finding is part of a \$2 million search for new creams or gels to protect people from sexually transmitted diseases, including AIDS. The researchers reported that bile acid provided 80 percent protection against genital herpes, caused by herpes simplex virus type 2.

#### "Three Drug Firm Executives Held in Japan AIDS Case"

Reuters (09/19/96)

In the latest repercussions of Japan's tainted blood scandal, the current president and two former presidents of the

Japanese pharmaceutical company Green Cross were arrested today on suspicion of professional negligence resulting in death. Takehiko Kawano, and his predecessors Renzo Matsushita and Takakazu Suyama, are suspected of having permitted the sale of unheated blood products even though they were aware of the HIV risk the products carried. A murder complaint was filed Wednesday by the family of a deceased AIDS patient against a former Health Ministry official. This marked the first formal complaint against a public official, and could lead to investigations of the government's role in the scandal.

#### "AIDS Seminar to Be Held in Nicaragua"

Xinhua News Agency (09/18/96)

Nicaragua will host health ministers from central American countries between Sept. 30 and Oct. 4 for a seminar to assess the HIV prevention efforts in the region. Representatives from the World Health Organization, the Panamerican Health Organization, the United Nations AIDS agency, and the U.S. International Agency for Development will attend. Nicaragua has the lowest AIDS rate of the countries in Central America, an official from the Nicaraguan Health Ministry said. A total of 264 HIV and AIDS cases have been reported, compared to Honduras, with 5,500 cases, the region's highest rate.

#### "Condom Day to Be Observed in East Nepal"

Xinhua News Agency (09/18/96)

A condom day program is being planned by the local Red Cross society in an eastern Nepali district, hoping to raise public awareness about preventing sexually transmitted diseases. During the event, information on the use of condoms for contraception and disease prevention will be distributed.

#### "Discarded Needles Spur Call for Reviewing Exchange Program"

American Medical News (09/09/96) Vol. 39, No. 34, P. 31

Concerns have been raised about the needle exchange program in Willimantic, Conn., following the collection of more than 350 discarded needles from city streets, lots, and alleys. The city's police chief and Windham County state's attorney have called upon the state to investigate the program. An examination of the 369 needles that were either turned in to police or collected in the city revealed that almost 73 percent were the brand used by the exchange program. State's Attorney Mark Solak has called for a law to make discarding used needles on the streets a felony. Dennis Knapp, a recovering drug addict who works for the program, noted that more needles would be discarded if the exchange program was not in place.

#### "The Return of an Ancient Killer"

Maclean's (09/09/96) Vol. 109, No. 36, P. 45; Chidley, Joe

Although tuberculosis (TB) was thought to have been nearly wiped out at least 15 years ago, it is currently the most deadly infectious disease in the world. While curable, TB killed almost 3 million people last year, and the World Health Organization estimates that one-third of the world's population is infected

with the TB bacterium. As new strains of the disease develop, chances increase that it will not be curable in the future, however. The WHO estimates that 50 million people now carry drug-resistant strains of the bacterium. Poor and homeless people, and those with compromised immunity--HIV-positive people, children, and the elderly, are at high-risk for TB. Treatment for the disease is inexpensive, but must be taken according to a strict six-month regimen. While Canada as a whole has a relatively low incidence of TB, the rate is high in its aboriginal community. Moreover, foreigners coming to Canada frequently bring TB with them, and screening for the disease is inadequate, says Toronto respirologist Monica Avendano.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-SEP-1996 10:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <0119NQZCLKN4000S31@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Thu,  
19 Sep 1996 10:15:45 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119NQZ7YE4G000RL7@PMDF.EOP.GOV> for  
levi\_j@a1.eop.gov; Thu, 19 Sep 1996 10:15:38 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119NQWN978Q00007Y@STORM.EOP.GOV> for  
levi\_j@a1.eop.gov; Thu, 19 Sep 1996 10:13:33 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA27832; Thu,  
19 Sep 1996 10:15:35 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 09:04:38.61

SUBJECT: memo as requested

TO: Remote Addressee ( ScottHitt@aol.com@INET@EOPMRX )  
READ:NOT READ

TEXT:

PRINTER FONT 18\_POINT\_ROMAN\_ITALIC  
Draft

PRINTER FONT 12\_POINT\_ROMAN  
MEMORANDUM TO ALL MEMBERS OF THE PRESIDENT'S ADVISORY COUNCIL ON  
HIV/AIDS

FROM: Dr. R. Scott Hitt, Chair

SUBJECT: Review of Draft National AIDS Strategy

At our September 1996 meeting, the Council agreed to review the preliminary draft copy of the National AIDS Strategy prepared by the Office of National AIDS Policy. The Council has agreed to offer our comments and suggestions to ONAP by no later than November 15, 1996. Release of a final draft to national, regional, and local organizations involved in the national response to the epidemic will follow in December.

To maximize our ability to influence the final product, it is imperative that we honor our commitment to maintain an embargo on this document. No copies -- or excerpts -- of this document can be shared or discussed with non

-Council members. This includes  
your employers, colleagues, and associates.

In order to meet our deadline, I will need comments from Council members and/or subcommittees by no later than close of business November 1. These suggestions will then be collated and delivered to ONAP by November 15. All comments and suggestions must be provided in written form.

Please let me know if you have any further questions. Thank you.

# Withdrawal/Redaction Marker

## Clinton Library

| DOCUMENT NO.<br>AND TYPE | SUBJECT/TITLE                                                                                                                                 | DATE       | RESTRICTION |
|--------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|
| 005. email               | From: Jeffrey Levi, To: Jeffrey Levi, Re: Appt. Request - Montoya, Daniel and Others [Personally Identifiable Information] [partial] (1 page) | 09/19/1996 | b(6)        |

### COLLECTION:

Clinton Presidential Records  
Automated Records Management System [Email]  
WHO  
OA/Box Number: 500000

### FOLDER TITLE:

[09/17/1996 - 09/24/1996]

2018-0759-F  
jn432

### RESTRICTION CODES

#### Presidential Records Act - [44 U.S.C. 2204(a)]

- P1 National Security Classified Information [(a)(1) of the PRA]
- P2 Relating to the appointment to Federal office [(a)(2) of the PRA]
- P3 Release would violate a Federal statute [(a)(3) of the PRA]
- P4 Release would disclose trade secrets or confidential commercial or financial information [(a)(4) of the PRA]
- P5 Release would disclose confidential advice between the President and his advisors, or between such advisors [(a)(5) of the PRA]
- P6 Release would constitute a clearly unwarranted invasion of personal privacy [(a)(6) of the PRA]

C. Closed in accordance with restrictions contained in donor's deed of gift.

PRM. Personal record misfile defined in accordance with 44 U.S.C. 2201(3).

RR. Document will be reviewed upon request.

#### Freedom of Information Act - [5 U.S.C. 552(b)]

- b(1) National security classified information [(b)(1) of the FOIA]
- b(2) Release would disclose internal personnel rules and practices of an agency [(b)(2) of the FOIA]
- b(3) Release would violate a Federal statute [(b)(3) of the FOIA]
- b(4) Release would disclose trade secrets or confidential or financial information [(b)(4) of the FOIA]
- b(6) Release would constitute a clearly unwarranted invasion of personal privacy [(b)(6) of the FOIA]
- b(7) Release would disclose information compiled for law enforcement purposes [(b)(7) of the FOIA]
- b(8) Release would disclose information concerning the regulation of financial institutions [(b)(8) of the FOIA]
- b(9) Release would disclose geological or geophysical information concerning wells [(b)(9) of the FOIA]

RECORD TYPE: PRESIDENTIAL (WAVES REQUEST)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 11:26:28.17

SUBJECT: Appt. request - Montoya, Daniel and others

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:NOT READ

TEXT:

Date Appointment with  
20-Sep-1996 SOCARIDES, RICHARD C

| Room No. | Bldg. | Requested by | Phone #  |
|----------|-------|--------------|----------|
| 166      | EOB   | Jeffrey Levi | 632-1090 |

---

Comments:

---

---

| TIME | VISITOR'S LAST, FIRST NAME | BIRTHDATE | SOC. SEC. # |
|------|----------------------------|-----------|-------------|
|------|----------------------------|-----------|-------------|

---

|         |                |        |     |
|---------|----------------|--------|-----|
| 10:45am | Montoya Daniel | (b)(6) | - - |
|         | Sorian Richard | (b)(6) | - - |

[005]

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 14:51:02.29

SUBJECT: RE: Ryan White Numbers

TO: Wm G. White ( Wm G. White@EOP@LNGTWY@EOPMRX )  
READ:NOT READ

TEXT:  
i think Steve was assuming we'd get this...but wantd some sense of proportions beyond that.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 10:38:40.02

SUBJECT: re quilt weekend

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:19-SEP-1996 10:54:49.96

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-SEP-1996 10:16:00.00

ATT BODYPART TYPE:B

ATT CREATOR: Richard Socarides

ATT SUBJECT: AIDS Quilt weekend

ATT TO: Jeffrey Levi ( LEVI\_J )

ATT TO: Jeremy D. Benami ( BENAMI\_J )

TEXT:

Marsha, Phil DuFour and I are meeting on Friday at 10:45 to talk about the Quilt and participation in related events that weekend. It would be great if you both could attend.

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:19-SEP-1996 16:13:20.47

SUBJECT: My whereabouts tomorrow

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:19-SEP-1996 18:28:33.18

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:19-SEP-1996 16:18:59.25

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:20-SEP-1996 09:48:42.90

TO: Richard Sorian ( SORIAN\_R ) (OPD)  
READ:NOT READ

TO: Carmena Parris ( PARRIS\_C ) (OPD)  
READ:20-SEP-1996 07:47:31.89

TEXT:  
I will be out of the office tomorrow. I will be back on Monday 9/23.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Richard Socarides ( SOCARIDES\_R ) (WHO)

CREATION DATE/TIME:19-SEP-1996 10:28:42.28

SUBJECT: AIDS Quilt weekend

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:19-SEP-1996 10:39:18.68

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)

READ:19-SEP-1996 10:53:20.78

TEXT:

Marsha, Phil DuFour and I are meeting on Friday at 10:45 to talk about the Quilt and participation in related events that weekend. It would be great if you both could attend.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: Wm G. White@EOP@LNGTWY@EOPMRX

CREATION DATE/TIME:19-SEP-1996 09:05:00.00

SUBJECT: VA/HUD Conference Action

TO: LEVI\_J ( LEVI\_J@A1@CD ) (WHO)

READ:19-SEP-1996 09:12:46.23

TEXT:

Message Creation Date was at 19-SEP-1996 09:07:00

----- Forwarded by Wm G. White/OMB/EOP on 09/19/96 08:49 AM  
-----

Barry T. Clendenin  
09/18/96 11:17:22 PM  
Record Type: Record

To: See the distribution list at the bottom of this message  
cc:  
Subject: VA/HUD Conference Action

----- Forwarded by Barry T. Clendenin/OMB/EOP on 09/18/96  
11:07 PM -----

Michael J. Mcdermott  
09/18/96 06:30:07 PM  
Record Type: Record

To: See the distribution list at the bottom of this message  
cc:  
Subject: VA/HUD Conference Action

The conferees closed debate on all titles of the FY 1997 VA/HUD Appropriations bill - except for Spina Bifida, Mental Health Parity, and the Newborn and Mother's Health Protection Act. There are several outstanding technical language issues regarding these additions to the bill that are being resolved. The outstanding issues may be resolved as early as this evening. Chairman Lewis hopes to get the completed conference agreement to the House Floor by Friday afternoon. Chairman Lewis, Chairman Bond, Mr. Obey, and several others expressed their strong intentions to keep this bill out of the CR and have it signed. Chairman Bond was especially vocal on this point. Staff is meeting tonight to try and work out some technical language issues concerning the three health care amendments. One of the issues is the potential delay of the Spina Bifida program until January 1, 1998.

The Conference agreement would provide:

Senate level for the Corporation for National and Community Service,

\$25 M budget amendment for HOPWA,

VA Comp. and Pen. Budget Amendment,

GNMA Supplemental on loan guarantee commitments,

VA \$100 M Supplemental for Comp. and Pen,

funding for a VA hospital at Travis, and

includes language in the Senate bill regarding a VA resource allocation study and the implementation of the recommendations.

The agreement would also adopt the new Senate account structure for HUD, and would fund VA, for the most part, at the lower Senate level.

The agreement DOES NOT include:

the .4% across-the-board cut included in the House bill,

House language pertaining to NSF and the purchase of a supercomputer,

House language prohibiting NASA from funding the Bion 11 and 12 programs,

House Superfund and Drinking Water language, and

House language regarding ROTC recruitment on college campuses.

Copies of the Conference Notes have been distributed to each of the relevant division offices. I have one as well if someone needs to make an additional copy.

Message Sent To: \_\_\_\_\_

Barry B. Anderson/OMB/EOP

Kenneth S. Apfel/OMB/EOP

Robert E. Barker/OA/EOP

Jeff Blaylock/OMB/EOP

Edward A. Brigham/OMB/EOP

Barry T. Clendenin/OMB/EOP

Ronald M. Cogswell/OMB/EOP

Richard P. Emery Jr./OMB/EOP

Michelle A. Enger/OMB/EOP

Robert S. Fairweather/OMB/EOP

Joseph Firschein/OMB/EOP

T J. Glauthier/OMB/EOP

Lawrence J. Haas/OMB/EOP

Adam Hoffberg/OMB/EOP

Sarah G. Horrigan/OMB/EOP  
Toni S. Hustead/OMB/EOP  
Steven J. Isakowitz/OMB/EOP  
Carline M Jelsma/OMB/EOP  
Heather A. Johnston/OMB/EOP  
James F. Jordan/OMB/EOP  
Alexander S. Keenan/OMB/EOP  
Charles E. Kieffer/OMB/EOP  
Charles Konigsberg/OMB/EOP  
Lisa M. Kountoupes/OMB/EOP  
Jacob J. Lew/OMB/EOP  
Jonna M. Long/OMB/EOP  
Larry R. Matlack/OMB/EOP  
Katherine L. Meredith/OMB/EOP  
Joseph J. Minarik/OMB/EOP  
Nancy A. Min/OMB/EOP  
Memphis A. Norman/OMB/EOP  
Kathleen Peroff/OMB/EOP  
Francis S. Redburn/OMB/EOP  
Alan B. Rhinesmith/OMB/EOP  
Nancy S. Ridenour/OMB/EOP  
Elizabeth L. Rossman/OMB/EOP  
Lynn C. Ross/OMB/EOP  
Kenneth L. Schwartz/OMB/EOP  
Alice E. Shuffield/OMB/EOP  
Hang T. Tran/OMB/EOP  
Pamela B. Van Wie/OMB/EOP  
Katherine M. Tyer/OMB/EOP  
Theodore Wartell/OMB/EOP  
Barry White/OMB/EOP  
David M. Zavada/OMB/EOP  
David J. Haun/OMB/EOP  
Alexandra Lehr/OMB/EOP  
Corey G. Lee/OMB/EOP

Message Sent To: \_\_\_\_\_

Thomas Reilly/OMB/EOP  
Michelle Hanson/OMB/EOP  
Ann Kendrall/OMB/EOP  
Corey G. Lee/OMB/EOP  
Mark E. Miller/OMB/EOP  
John M. Richardson/OMB/EOP  
Parashar B. Patel/OMB/EOP  
Victoria A. Wachino/OMB/EOP  
Wm G. White/OMB/EOP  
Richard J. Turman/OMB/EOP

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:19-SEP-1996 11:57:52.97

SUBJECT: WEEKLY TIME AGAIN

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)

READ:19-SEP-1996 12:07:05.84

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)

READ:19-SEP-1996 16:07:28.21

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)

READ:NOT READ

TO: Dennis Burke ( BURKE\_D ) (OPD)

READ:19-SEP-1996 13:40:55.63

TO: Diane Regas ( REGAS\_D ) (OPD)

READ:19-SEP-1996 13:36:25.74

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:19-SEP-1996 12:03:24.49

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)

READ:19-SEP-1996 13:01:46.97

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)

READ:19-SEP-1996 16:01:33.43

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)

READ:19-SEP-1996 11:59:08.44

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:19-SEP-1996 13:01:44.75

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

READ:20-SEP-1996 11:52:47.43

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)

READ:19-SEP-1996 12:07:23.16

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)

READ:19-SEP-1996 13:37:27.91

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)

READ:19-SEP-1996 11:58:13.45

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)

READ:19-SEP-1996 12:25:33.79

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:19-SEP-1996 16:34:52.55

TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S ) (OPD)  
READ:19-SEP-1996 19:12:52.30

TEXT:

I'd like your weekly before you leave today. THANK YOU for sending such good stuff last week.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 10:29:12.14

SUBJECT: daily news

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:19-SEP-1996 11:07:09.55

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)  
READ:19-SEP-1996 13:38:02.28

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:19-SEP-1996 11:50:46.03

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:19-SEP-1996 10:15:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 09/19/96

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

AIDS Daily Summary  
September 19, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"Virus Chase: Five Teams Pursue Herpes Drug"

"Boxer Morrison Plans Comeback"

"Ontario to Promote Hepatitis B Shots"

"No-Consent Tests Near on Humans"

"Researchers Develop Cream to Prevent Herpes"

"Three Drug Firm Executives Held in Japan AIDS Case"

"AIDS Seminar to Be Held in Nicaragua"

"Condom Day to Be Observed in East Nepal"

## "Discarded Needles Spur Call for Reviewing Exchange Program"

### "The Return of an Ancient Killer"

\*\*\*\*\*

## "Virus Chase: Five Teams Pursue Herpes Drug"

Wall Street Journal (09/19/96) P. B6; Bishop, Jerry E.

The discovery of a weakness in a herpes virus called cytomegalovirus (CMV), which causes blindness in AIDS patients, has resulted in a race to develop drugs against CMV and other herpes viruses. Research teams at SmithKline Beecham, Boehringer Ingelheim, and Monsanto reported the finding simultaneously and are racing to develop drugs that take advantage of it. Scientists at Agouron Pharmaceuticals and Arris Pharmaceutical are also following the same strategy to rush drug development. The research follows the same path that was used to develop protease inhibitors--finding a drug that will block a protein the virus needs to replicate.

## "Boxer Morrison Plans Comeback"

USA Today (09/19/96) P. 1C; Saraceno, Jon

Tommy Morrison, the heavyweight fighter who retired from the sport eight months ago after learning that he was infected with HIV, is planning to announce that he will return to the ring. Although the leading boxing-rich states require fighters to test negative for HIV, Morrison could potentially fight in about six states or overseas--or challenge the legality of the requirement. The Nevada boxing commission suspended Morrison because he tested positive, and the executive director of that commission said he would "expect all states that have boxing commissions to honor our suspension."

## "Ontario to Promote Hepatitis B Shots"

Toronto Globe and Mail (09/18/96) P. A7; Immen, Wallace

High school students in Ontario would be vaccinated for hepatitis B under a voluntary program to be announced this week. The virus, which is spread through blood or sexual contact, can cause liver damage. The risk for high school students has increased due to the trend of body piercing and tattooing. Hepatitis B is approximately 100 times more infectious than AIDS, according to the Canadian Liver Foundation.

## "No-Consent Tests Near on Humans"

Chicago Tribune (09/18/96) P. 1-1; Schreuder, Cindy; Hutchcraft, Chuck

Chicago's Cook County Hospital is preparing to test an experimental blood substitute that would be given to trauma patients unable to give their consent. The substitute offers the critical time-saving advantage of not having to be matched to a patient's blood type. The testing in Chicago is part of a national study that is on hold until the federal government approves rules that will allow promising experimental therapies to be given to trauma patients without their consent. Blood substitutes, which can be stored much longer than donated blood, could be also used to meet demands when the blood supply is low.

Although researchers have been trying to find a substitute for blood for hundreds of years, its importance was highlighted after some people contracted HIV via contaminated blood transfusions.

#### "Researchers Develop Cream to Prevent Herpes"

Reuters (09/18/96)

A cream to prevent genital herpes, and possibly other sexually transmitted diseases, has been developed from human bile acid, researchers at Cincinnati's Children's Hospital Medical Center reported. The finding is part of a \$2 million search for new creams or gels to protect people from sexually transmitted diseases, including AIDS. The researchers reported that bile acid provided 80 percent protection against genital herpes, caused by herpes simplex virus type 2.

#### "Three Drug Firm Executives Held in Japan AIDS Case"

Reuters (09/19/96)

In the latest repercussions of Japan's tainted blood scandal, the current president and two former presidents of the Japanese pharmaceutical company Green Cross were arrested today on suspicion of professional negligence resulting in death. Takehiko Kawano, and his predecessors Renzo Matsushita and Takakazu Suyama, are suspected of having permitted the sale of unheated blood products even though they were aware of the HIV risk the products carried. A murder complaint was filed Wednesday by the family of a deceased AIDS patient against a former Health Ministry official. This marked the first formal complaint against a public official, and could lead to investigations of the government's role in the scandal.

#### "AIDS Seminar to Be Held in Nicaragua"

Xinhua News Agency (09/18/96)

Nicaragua will host health ministers from central American countries between Sept. 30 and Oct. 4 for a seminar to assess the HIV prevention efforts in the region. Representatives from the World Health Organization, the Panamerican Health Organization, the United Nations AIDS agency, and the U.S. International Agency for Development will attend. Nicaragua has the lowest AIDS rate of the countries in Central America, an official from the Nicaraguan Health Ministry said. A total of 264 HIV and AIDS cases have been reported, compared to Honduras, with 5,500 cases, the region's highest rate.

#### "Condom Day to Be Observed in East Nepal"

Xinhua News Agency (09/18/96)

A condom day program is being planned by the local Red Cross society in an eastern Nepali district, hoping to raise public awareness about preventing sexually transmitted diseases. During the event, information on the use of condoms for contraception and disease prevention will be distributed.

#### "Discarded Needles Spur Call for Reviewing Exchange Program"

American Medical News (09/09/96) Vol. 39, No. 34, P. 31

Concerns have been raised about the needle exchange program

in Willimantic, Conn., following the collection of more than 350 discarded needles from city streets, lots, and alleys. The city's police chief and Windham County state's attorney have called upon the state to investigate the program. An examination of the 369 needles that were either turned in to police or collected in the city revealed that almost 73 percent were the brand used by the exchange program. State's Attorney Mark Solak has called for a law to make discarding used needles on the streets a felony. Dennis Knapp, a recovering drug addict who works for the program, noted that more needles would be discarded if the exchange program was not in place.

"The Return of an Ancient Killer"

Maclean's (09/09/96) Vol. 109, No. 36, P. 45; Chidley, Joe

Although tuberculosis (TB) was thought to have been nearly wiped out at least 15 years ago, it is currently the most deadly infectious disease in the world. While curable, TB killed almost 3 million people last year, and the World Health Organization estimates that one-third of the world's population is infected with the TB bacterium. As new strains of the disease develop, chances increase that it will not be curable in the future, however. The WHO estimates that 50 million people now carry drug-resistant strains of the bacterium. Poor and homeless people, and those with compromised immunity--HIV-positive people, children, and the elderly, are at high-risk for TB. Treatment for the disease is inexpensive, but must be taken according to a strict six-month regimen. While Canada as a whole has a relatively low incidence of TB, the rate is high in its aboriginal community. Moreover, foreigners coming to Canada frequently bring TB with them, and screening for the disease is inadequate, says Toronto respirologist Monica Avendano.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:19-SEP-1996 10:16:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <01I9NQZCLKN4000S31@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Thu, 19 Sep 1996 10:15:45 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9NQZ7YE4G000RL7@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Thu, 19 Sep 1996 10:15:38 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9NQWN978Q00007Y@STORM.EOP.GOV> for levi\_j@a1.eop.gov; Thu, 19 Sep 1996 10:13:33 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA27832; Thu, 19 Sep 1996 10:15:35 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 13:03:44.04

SUBJECT: RE: MC

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:19-SEP-1996 13:29:14.46

TEXT:

i sent her an e-mail, she called the other day when you were out  
-- i told her you would be calling. Let's not forget to include  
inviting her to any of the events.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:19-SEP-1996 10:39:45.45

SUBJECT: RE: AIDS Quilt weekend

TO: Richard Socarides (SOCARIDES\_R) (WHO)

READ:19-SEP-1996 10:58:51.56

CC: Jeremy D. Benami (BENAMI\_J) (WHO)

READ:19-SEP-1996 10:53:56.63

CC: Patsy Fleming (FLEMING\_P) (WHO)

READ:19-SEP-1996 11:02:21.81

TEXT:

i am in chicago tomorrow -- i am passing this on to Patsy; we will definitely be represented -- but where is the meeting?

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:19-SEP-1996 12:59:37.35

SUBJECT: MC

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:19-SEP-1996 13:03:57.92

TEXT:

Have you called MC yet? If not, we could call together re progress and possible invitees.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

CREATION DATE/TIME:20-SEP-1996 18:19:30.75

SUBJECT: RASCO 4 week schedule

TO: David S. Beaubaire ( BEAUBAIRE\_D ) (WHO)  
READ:21-SEP-1996 11:56:34.35

TO: Janet B. Abrams ( ABRAMS\_J ) (VPO)  
READ:20-SEP-1996 18:49:40.32

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:NOT READ

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:23-SEP-1996 10:29:44.27

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:20-SEP-1996 18:21:27.84

TO: Pamela Cicetti ( CICETTI\_P ) (WHO)  
READ:20-SEP-1996 18:19:48.21

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:NOT READ

TO: Deborah L. Fine ( FINE\_D ) (OPD)  
READ:21-SEP-1996 11:39:23.57

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:20-SEP-1996 19:15:12.83

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ:23-SEP-1996 16:23:45.34

TO: Dorothy K. Craft ( CRAFT\_D ) (OPD)  
READ:24-SEP-1996 10:16:44.34

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:20-SEP-1996 19:06:27.31

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:23-SEP-1996 09:00:08.37

TO: Cathy R. Mays ( MAYS\_C ) (OPD)  
READ:23-SEP-1996 09:11:38.81

TO: Carol H. Rasco ( RASCO\_C ) (WHO)  
READ:20-SEP-1996 18:25:43.63

TO: Bruce N. Reed ( REED\_B ) (WHO)  
READ:23-SEP-1996 10:22:50.46

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:23-SEP-1996 09:10:04.23

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:20-SEP-1996 18:34:07.98

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:23-SEP-1996 11:40:24.89

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:20-SEP-1996 18:30:37.79

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:20-SEP-1996 18:40:08.11

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:24-SEP-1996 10:01:00.02

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:20-SEP-1996 18:20:29.21

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:05:32.73

TEXT:

PRINTER FONT 12\_POINT\_ROMAN  
TO: DPC STAFF  
FR: JILL PIZZUTO  
RE: CHR CALENDAR HIGHLIGHTS

-----  
-----

September 23:  
10:30a California Controllers Kathleen Connell & Brad Kane re:  
welfare reform

2:05p Depart National  
5:54p Arrive Owensboro, KY

September 24:  
Owensboro, KY / Rolling Heights Family Development Center  
CHR / Keynote Speaker for Opening of new center

4:31p Depart Owensboro, KY  
9:29p Arrive National

September 25:  
1:00p NGA/APWA/NCSL re: welfare reform  
7:15 p Depart National  
9:30p Arrive Orlando

September 26:  
Orlando, FL  
10:00a State/group meetings  
12:00p Families & Communities Together Prevention Works

## Conference

Florida Network of Youth & Family Services Convention  
CHR / Keynote Speaker + three small group meetings

September 27:

Tallahassee, FL

8:00a Depart Orlando

9:10p Arrive Tallahassee

am/pm State/group meetings

5:00p Reception w/ Florida Women Leaders

September 28:

Tallahassee

9:00a Florida State University symposium on women's issues

12:45p CHR gives Keynote address at luncheon

2:55p Departs Tallahassee

7:00p Arrive National

September 29:

4:00p Metropolitan Memorial United Methodist Church  
dedication to Bishop Felton May

September 30:

2:00p Congressional Hunger Center meeting

5:00p DPC Meeting re: Partnership Project

Oct. 2:

10:00a Robert Wood Johnson Foundation meeting

1:00p NGA/APWA/NCSL weekly

Oct 4:

11:00a Kellogg Fellows

1:30p Community Enterprise Board bi

-weekly meeting / CHR to  
address

Oct.7

-9:

TENT Wisconsin/Wingspread Conference

Oct. 11:

9:30a

-4:30p Child Welfare Conference

Oct.11

-15:

PERSONAL Leave

Oct. 15:

TBA p.m. Depart for Flint, MI

Oct. 16:

9:00a Mott's Children's Health Center Tuuri Day Conference,  
Flint, MI.

TBA Return DC

Oct. 17:

2:00p Partnership Steering Committee meeting

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:20-SEP-1996 17:30:00.00

SUBJECT: CDC AIDS Daily Summary 09/20/96

TO: levi\_j ( levi\_j@A1@CD ) (WHO)

READ:23-SEP-1996 08:59:37.69

TEXT:

AIDS Daily Summary  
September 20, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"Confidential AIDS Data Given to Paper"

"Health Officials Are Urging a Focus on AIDS in Prisons"

"Morrison Plans One More Fight Despite H.I.V.-Positive Status"

"Rare, Deadly Germs Discovered Globally"

"The Trades of the Tricks"

"Disease Threat Arriving via Foreign Ships"

"Tennessee Court Rules for Insurer in Failure to Disclose Case Involving HIV-Positive Male"

"Occupational Risks Associated With Tuberculosis Listed"

"Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection"

"HIV Patient Denied Hospital Admission"

\*\*\*\*\*

"Confidential AIDS Data Given to Paper"

Washington Post (09/20/96) P. A7

The Tampa Tribune was anonymously sent a copy of a confidential computer disk containing the names of 4,000 AIDS patients. The disk was mailed to the newspaper with a letter which said the disk was dropped outside a bar by a drunken public health worker who had showed the list to friends on a laptop computer. The writer also claimed to have made a copy of the disk. The newspaper reports that it gave a copy of the disk and letter to the Florida Department of Health and Rehabilitative Services, which is investigating the incident. The public health worker, one of three people with access to the information, has been placed on paid administrative leave. A state health

department representative called the incident "probably about the worst thing that could happen in the AIDS program."

"Health Officials Are Urging a Focus on AIDS in Prisons"  
Philadelphia Inquirer (09/20/96) P. A25; Vedantam, Shankar

The rate of AIDS in U.S. prisons is six times greater than the national average, federal researchers report, adding that about 22 million Americans enter and leave jails and prisons each year. Unsafe sex practices and needle sharing put inmates at high risk, and increase the chance that they will carry the virus with them when released. Researchers at the Centers for Disease Control and Prevention reported their findings Thursday in the American Journal of Public Health. They are supporting AIDS education for prisoners, and the distribution of condoms and clean needles in jails and prisons. Most correctional facilities are reluctant to provide prisoners with condoms and needles, however, because they see such practices as condoning activity they do not allow. Researchers and prison advocates say this position is unrealistic, and increases the risk of spreading HIV.

"Morrison Plans One More Fight Despite H.I.V.-Positive Status"  
New York Times (09/20/96) P. B8; Roberts, Selena

Although boxer Tommy Morrison announced in February, after learning that he is infected with HIV, that he would "absolutely" not box again, he said Thursday that he wants to fight "one last time." Morrison was suspended from the sport in Nevada because he tested positive for the virus that causes AIDS, but some states do not screen boxers for HIV. If he can find an opponent, Morrison said he wants to schedule a fight to benefit his foundation, Knockout AIDS. He says he has been convinced by medical evidence that HIV cannot be spread in the ring. His promoter, Tony Holden, is not yet convinced of this, however, and says that, until he is, he will not promote such a match. Boxer Ross Puritty said that he is willing to fight Morrison "if the money is right."

"Rare, Deadly Germs Discovered Globally"  
USA Today (09/20/96) P. 12D; Manning, Anita

New germs, some deadly, are emerging all over the world, researchers from the Centers for Disease Control and Prevention report. Among the new microbes discussed at a meeting of the American Society for Microbiology, was hepatitis G, a new form of the virus. that appears to be transmitted in the blood but has not been linked to disease. The researchers also pointed to bartonella, discovered in 1990, as the cause of various illnesses in healthy people, but which can be fatal to people with compromised immunity. In AIDS patients, it causes an illness that mimics Kaposi's sarcoma. Dr. Jane E. Koehler says it is critical for doctors to recognize the difference, because the treatment is completely different.

"The Trades of the Tricks"  
Washington Post (09/19/96) P. C1; Bowles, Scott

Police say that escort services have become popular among

white-collar johns in the Washington, D.C., area. Using cellular phones, voice mail systems, and computers to process credit-card payments, call girls in the region often operate as professionals through agencies that often escape prosecution. However, these women note that they still fear contracting HIV. While they usually demand that a condom be worn, they "still live scared that the next guy has AIDS. You just have to weigh the risk against how much money you make," said one call girl.

#### "Disease Threat Arriving via Foreign Ships"

USA Today (09/19/96) P. 3A; Tyson, Rae

Foreign ships coming to the United States are carrying bacteria that cause cholera and other deadly diseases thought to have been eradicated here. More than 21 billion gallons of ballast water, carrying cholera, E. coli, botulism, salmonella, cryptosporidium, and hepatitis A, are dumped by the ships that enter U.S. waters each year. The bacteria infect shellfish which, when eaten raw, can infect humans. Congress is now considering implementing new ballast water regulations.

#### "Tennessee Court Rules for Insurer in Failure to Disclose Case Involving HIV-Positive Male"

Reuters (09/19/96)

A life insurance company's decision that a man who did not reveal that he had HIV was not eligible for disability benefits was upheld by a Tennessee Court of Appeals. Krystof Krakowiak filed a lawsuit against the Paul Revere Life Insurance, claiming that his condition should not have been covered under the company's pre-existing conditions clause. The company held that AIDS is not a pre-existing condition, but rather an illness, and that the policy did not cover pre-existing illnesses.

#### "Occupational Risks Associated With Tuberculosis Listed"

Reuters (09/19/96)

Inhalation therapists, lower-paid health care workers, and funeral directors are at increased risk for tuberculosis (TB) than the general population, federal researchers report. Matthew T. McKenna and colleagues at the Centers for Disease Control and Prevention say that people with the "most intensive interaction with patients with pulmonary disease" are at high risk for contracting TB. They suggest that the risk of TB in the community should be considered when implementing worksite TB control measures.

#### "Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection"

Journal of the American Medical Association (09/11/96) Vol. 276, No. 10, P. 762; Moore, Richard D.

While zidovudine is known to provide a survival benefit for advanced AIDS patients, the length of time of this benefit is not known. However, researchers at the Johns Hopkins University School of Medicine now report in the Archives of Internal Medicine that the survival advantage lasts between one and two years. They made the estimate based on data from nearly 400

HIV-infected patients who were followed for three years. Compared to no treatment, a significant benefit from zidovudine was found during the first year of therapy. A diminishing benefit was found, however, at one to two years.

"HIV Patient Denied Hospital Admission"

American Medical News (09/09/96) Vol. 39, No. 34, P. 30

A federal trial court ruled that an Ohio hospital violated the Americans with Disabilities Act when it refused to admit an HIV-positive patient. The patient was taken to the emergency room after having an adverse reaction to a new medication. The attending physician determined that the patient had to be admitted, but the hospital's admitting physician denied the patient's admission. The patient was transferred to a medical college hospital, where the staff determined that he was having a simple, but severe, allergic reaction to his medication. The patient sued the first hospital and the admitting physician for violating the ADA, the Federal Rehabilitation Act, and the Emergency Medical Treatment and Active Labor Act. The trial court ruled against the hospital and the physician on the ADA claim only. The patient was not entitled to damages, but the hospital was enjoined from further violations of the ADA and ordered to post signs to inform HIV-infected patients of their protection from discrimination under the ADA.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 17:31:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9PKGD7968000UWA@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Fri,  
20 Sep 1996 17:30:16 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9PKG9HAN4000VOT@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Fri, 20 Sep 1996 17:30:08 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9PKDMC86A00007L@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Fri, 20 Sep 1996 17:28:00 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id RAA03251; Fri,  
20 Sep 1996 17:30:09 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:20-SEP-1996 15:48:00.00

SUBJECT: New Information from ACTIS 09/19/96 (2 of 2)

TO: levi\_j ( levi\_j@A1@CD ) (WHO)

READ:23-SEP-1996 08:58:09.16

TEXT:

New Information from ACTIS

September 19, 1996

2 of 2

PROTOCOL NUMBER: FDA 256A.

TITLE: A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111  
Administered Intrathecally to Cancer and AIDS Patients With  
Chronic Pain.

PHASE: Phase II / Phase III.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. Chronic pain related to HIV or cancer. 2. Unsatisfactory response to opioid therapy (intolerable side effects or inadequate pain relief).

#### PATIENT INCLUSION CRITERIA

-----

#### SPECIFICATION CRITERIA:

Patients must have:

1. Chronic pain related to HIV or cancer.
2. Unsatisfactory response to prior opioid therapy.
3. Life expectancy > 3 months (or 1 month if an infusion pump is in place).

AGE: 18 Years - 99 Years.

SEX: M. F.

#### REPRODUCTIVE SPECIFICATION:

Not pregnant. Not breast-feeding.

#### CONCURRENT MEDICATION:

Allowed: Rescue analgesia.

#### LABORATORY VALUES AT ENTRY

-----

CD4 (T4 CELL) COUNT: Unspecified cells/mm3.

PATIENT EXCLUSION CRITERIA

SPECIFICATION CRITERIA:

Patients with the following prior conditions are excluded:  
History of heart disease, heart failure, or asthma.

AGE: 01 Days - 17 Years.

REPRODUCTIVE SPECIFICATION:

Pregnant. Breast-feeding.

CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:  
Signs of sepsis or inadequately treated infection.

GENERIC DRUG NAME

Drug 1: SNX-111. Calcium Channel Blocker.

DRUG COMPANIES

Drug 1: Neurex Corporation  
3760 Haven Avenue  
Menlo Park, CA 94025  
Contact: Unspecified (415) 853-1500.

PARTICIPATING UNITS

0000003563:  
Clinical Solutions  
103 Carnegie Center / Suite 106  
Princeton, NJ 08540  
Contact: Unspecified (800) 577-8839 X 92  
OPEN / USA accrual (Call for study sites) 960604.

\*\*\*\*\*

PROTOCOL NUMBER: FDA 257A.

TITLE: Study of the Safety and Effects of Two Doses of SPC3,  
Administered Daily Intravenously in HIV-1 Seropositive  
Patients. (FDA DISCLAIMER: The FDA encourages the inclusion of  
females of childbearing potential in study protocols, but the

sponsor of this protocol specifically excludes females of childbearing potential from this study and includes only females who are sterile. Any questions about these inclusion/exclusion criteria should be directed to the study's contact person.)

PHASE: Phase I / Phase II.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV seropositive for at least 6 months. 2. CD4  $\geq$  100 cells/mm<sup>3</sup>. 3. HIV RNA PCR (Amplicor) > 10000 copies/ml. 4. No significant active opportunistic infection or tumor at study entry.

PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. HIV seropositive for at least 6 months.
2. CD4  $\geq$  100 cells/mm<sup>3</sup>.
3. HIV RNA PCR (Amplicor) > 10000 copies/ml.
4. No significant active opportunistic infection or tumor at study entry.

FDA DISCLAIMER: The FDA encourages the inclusion of females of childbearing potential in study protocols, but the sponsor of this protocol specifically excludes females of childbearing potential from this study and includes only females who are sterile. Any questions about these inclusion/exclusion criteria should be directed to the study's contact person.

AGE: 18 Years - 65 Years.

SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Postmenopausal or permanently sterile because of tubal ligation, hysterectomy, or oophorectomy. Not breast-feeding.

PRIOR MEDICATION:

Allowed: Prior antiretrovirals.

CONCURRENT MEDICATION:

Allowed: Antiretrovirals provided regimen has been stable for at least 6 weeks prior to study screening.

LABORATORY VALUES AT ENTRY

-----

HEMOGLOBIN: > 10 g/dl.

CD4 (T4 CELL) COUNT:  $\geq$  100 cells/mm<sup>3</sup>. ( 100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus ).

BILIRUBIN:  $\leq$  3 x ULN mg/dl. (ULN = upper limit of normal).

SGOT (AST): <= 3 x ULN.  
SGPT (ALT): <= 3 x ULN.  
CREATININE: <= 1.6 mg/dl.  
KARNOFSKY: > 70.  
OTHER LABORATORY VALUES: Neutrophils >= 500 cells/mm3.

#### PATIENT EXCLUSION CRITERIA

-----

##### SPECIFICATION CRITERIA:

Patients with the following prior condition are excluded:  
History of relevant drug hypersensitivity.

AGE: 01 Days - 17 Years. 66 Years - 99 Years.

##### REPRODUCTIVE SPECIFICATION:

Future reproduction. Breast-feeding.

##### PRIOR MEDICATION:

Excluded: Investigational drug within the past 4 weeks.

##### CONCURRENT MEDICATION:

Excluded: Any drug that may interact with SPC3 (e.g., suramin).

##### CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following conditions are excluded:  
Inability to communicate with investigator or deemed likely to be noncompliant on study.

#### GENERIC DRUG NAME

-----

Drug 1: Synthetic Peptide Construction 3. Antiretroviral.

#### DRUG COMPANIES

-----

Drug 1: Columbia Research Laboratories Incorporated  
100 North Village Avenue / Suite 32  
Rockville Centre, NY 11570  
Contact: Dr Howard Levine (516) 766-2660.

#### PARTICIPATING UNITS

-----

0000003590:  
Roger Williams Medical Center  
825 Chalkstone Avenue  
Providence, RI 02908

Contact: Grace Acetta  
OPEN 960822.

(401) 456-2532

\*\*\*\*\*

## DRUG RECORDS

### Accession Number:

DRG-0250.

### Generic Name:

SNX-111 (FDA 256A).

### Protocol Number(s):

Open FDA 256A

### Alias/Trade Name:

SNX 111 (MeSH). omega-Conopeptide MVIIA (MeSH). omega-Conotoxin MVIIA,  
Conus magus (MeSH).

### Chemical Abstract Name:

omega-Conotoxin MVIIA (CHEMLINE).

### CAS Registry Number:

107452-89-1 (CHEMLINE).

### Drug Company(ies):

Neurex Corporation

3760 Haven Avenue

Menlo Park, CA 94025

Contact: Unspecified (415) 853-1500.

### Therapeutic Classification:

Calcium Channel Blocker (CHEMLINE).

### Drug Description:

Synthetic homologue of omega-conopeptide.

(J Pharmacol Exp Ther 1995 Aug;274(2) p 666-72)

### Pharmacology:

MODE OF ACTION: Relieves pain by interfering with the  
neurotransmission of pain impulses. Blocks neuronal N-type  
voltage-sensitive calcium channels.

(FDA 256A; J Pharmacol Exp Ther 1995 Aug;274(2) p 666-72)

### Contraindications:

Contraindicated in pregnant and nursing women.

(FDA 256A)

### Mode of Delivery:

Intrathecal. (FDA 256A)

### AIDS-Related Uses:

Pain related to HIV. (FDA 256A)

### Other Uses:

Pain related to cancer.

(FDA 256A)

### Bibliographic References:

95363679. Xiao WH, Bennett GJ. Synthetic omega-conopeptides  
applied to the site of nerve injury suppress neuropathic pains in  
rats. J Pharmacol Exp Ther 1995 Aug;274(2):666-72.

95315196. Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K,

Adriaenssens P, Ramachandran J. Structure-activity analysis of a  
Conus peptide blocker of N-type neuronal calcium channels.  
Biochemistry 1995 Jun 27;34(25):8076-81.

95126938. Kim JI, Takahashi M, Ohtake A, Wakamiya A, Sato K. Tyr13 is  
essential for the activity of omega-conotoxin MVIIA and GVIA,  
specific N-type calcium channel blockers. Biochem Biophys Res Commun  
1995 Jan 17;206(2):449-54.

95067173. Hovda DA, Fu K, Badie, H, Samii A, Pinanong P, Becker DP.  
Administration of an omega-conopeptide one hour following traumatic  
brain injury reduces 45calcium accumulation. Acta Neurochir Suppl  
(Wien) 1994;60:521-3.

\*\*\*\*\*

Accession Number:

DRG-0251.

Generic Name:

Synthetic Peptide Construction 3 (FDA 257A).

Protocol Number(s):

Open FDA 257A

Alias/Trade Name:

SPC3 (FDA 257A). SPC3 peptide (MeSH).

Drug Company(ies):

Columbia Research Laboratories Incorporated

100 North Village Avenue / Suite 32

Rockville Centre, NY 11570

Contact: Dr Howard Levine (516) 766-2660.

Therapeutic Classification:

Antiretroviral (FDA 257A).

Drug Description:

Synthetic multibranched peptide containing eight HIV-1 gp120 V3  
loop GPGRF motifs.

(Biochemistry 1995 Jul 4;34(26) p 8294-8)

Pharmacology:

MODE OF ACTION: Data suggest that SPC3 prevents HIV-1 attachment  
to the surface of CD4- cells that express galactosylceramide, an  
alternative receptor for HIV-1 gp120. In CD4+ lymphocytes, SPC3  
interferes with a post-binding step necessary for virus entry into  
the cell.

(Proc Natl Acad Sci USA 1995 May 23;92(11) p 4867-71)

Contraindications:

Contraindicated in women of reproductive potential.

(FDA 257A)

Mode of Delivery:

Intravenous. (FDA 257A)

AIDS-Related Uses:

HIV infection. (FDA 257A)

Bibliographic References:

MED/95281557. Yahi N, Fantini J, Baghdiguian S, Mabrouk K,  
Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM. SPC3, a

synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4867-71.

\*\*\*\*\*

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 15:49:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <01I9PGVYXEJK0011SU@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Fri,

20 Sep 1996 15:48:16 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9PGVWTBCG000VL3@PMDF.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 15:48:13 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9PGTBO1RG00007L@STORM.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 15:46:08 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id PAA20990; Fri,

20 Sep 1996 15:48:17 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:20-SEP-1996 16:33:00.00

SUBJECT: New Information from ACTIS 09/19/96 (1 of 2)

TO: levi\_j ( levi\_j@AI@CD ) (WHO)

READ:23-SEP-1996 08:58:34.64

TEXT:

September 19, 1996

1 of 2

### NEW INFORMATION FROM ACTIS

The AIDS Clinical Trials Information Service (ACTIS) is a central resource providing current information on federally and privately sponsored clinical trials for AIDS patients and others infected with HIV. This service is a Public Health Service project produced collaboratively by the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institute of Allergy and Infectious Diseases, and the National Library of Medicine. NAC ONLINE, the computerized information service of the CDC National AIDS Clearinghouse, will alert you to any new information collected by ACTIS.

Descriptions of four clinical trials and two drugs added to the ACTIS database are provided below.

For more information, call the ACTIS toll-free number to talk with a health specialist. On request, you can also obtain a printout of a customized search of the clinical trials databases. The information can also be accessed directly by subscribers through two online databases, AIDSTRIALS and AIDSDRUGS, available through the National Library of Medicine.

### AIDS CLINICAL TRIALS INFORMATION SERVICE

1-800-TRIALS-A

(1-800-874-2572)

FAX: 1-301-738-6616

TTY/TDD: 1-800-243-7012

International Line: 1-301-217-0023

\*\*\*\*\*

PROTOCOL NUMBER: FDA 229D.

TITLE: A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs.

PHASE: Phase II.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV infection. 2. Antiretroviral naive (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs. 3. No more than 2 weeks of prior treatment with a protease inhibitor.

PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. HIV infection.
2. Antiretroviral naive (i.e., less than 4 weeks of prior treatment) to at least one of the licensed nucleoside drugs.
3. No more than 2 weeks of prior treatment with a protease inhibitor.

AGE: 13 Years - 99 Years.

SEX: M. F.

LABORATORY VALUES AT ENTRY

-----

CD4 (T4 CELL) COUNT: Unspecified cells/mm3.

PATIENT EXCLUSION CRITERIA

-----

AGE: 01 Days - 12 Years.

PRIOR MEDICATION:

Excluded:

1. More than 4 weeks of the prior nucleoside antiretroviral selected for the patient's regimen.
2. More than 2 weeks of any protease inhibitor.

CONCURRENT MEDICATION:

Excluded: Other protease inhibitors.

GENERIC DRUG NAME

-----

Drug 1: Saquinavir mesylate. Protease inhibitor.

Drug 2: Zidovudine. Antiretroviral.

Drug 3: Zalcitabine. Antiretroviral.

Drug 4: Didanosine. Antiretroviral.

Drug 5: Stavudine. Antiretroviral.

Drug 6: Lamivudine. Antiretroviral.

## DRUG TRADE NAME

-----

Drug 1: Invirase.  
Drug 2: Retrovir.  
Drug 3: HIVID.  
Drug 4: Videx.  
Drug 5: Zerit.  
Drug 6: Epivir.

## DRUG COMPANIES

-----

Drug 1: Hoffmann - La Roche Incorporated  
340 Kingsland Street  
Nutley, NJ 07110-1199  
Contact: Professional Services (800) 526-6367.

Drug 2: Glaxo Wellcome  
5 Moore Drive / PO Box 13398  
Research Triangle Park, NC 27709  
Contact: Department of Consumer Affairs (800) 437-0992 X 7900.

Drug 3: Hoffmann - La Roche Incorporated  
340 Kingsland Street  
Nutley, NJ 07110-1199  
Contact: Professional Services (800) 526-6367.

Drug 4: Bristol - Myers Squibb Company  
2400 West Lloyd Expressway  
Evansville, IN 47721-0001  
Contact: Information (800) 662-7999.

Drug 5: Bristol - Myers Squibb Company  
2400 West Lloyd Expressway  
Evansville, IN 47721-0001  
Contact: Information (800) 662-7999.

Drug 6: Glaxo Wellcome  
5 Moore Drive / PO Box 13398  
Research Triangle Park, NC 27709  
Contact: Department of Consumer Affairs (800) 437-0992 X 7900.

## END POINT

-----

Drug efficacy, toxicity.

## PARTICIPATING UNITS

-----

0000003604:

UCSD Treatment Center  
2760 Fifth Avenue / 3rd Floor  
San Diego, CA 92103-6329

Contact: Ron Snyder (619) 543-8080  
OPEN 960916.

0000003605:

Mount Zion Hospital of UCSF  
2300 Sutter Street / Suite 202  
San Francisco, CA 94115

Contact: John Sayre (415) 885-7737  
OPEN 960916.

0000003462:

San Francisco Veterans Administration Medical Center  
4150 Clement Street  
San Francisco, CA 94121

Contact: Sandy Charles (415) 221-4810 X 3763  
OPEN 960916.

0000003609:

AIDS Research Center  
Dept of Veterans Affairs / 3801 Miranda Avenue / III-ID  
Palo Alto, CA 94304

Contact: Mark Mistal (415) 493-5000 X 64926  
OPEN 960916.

0000001499:

University of Colorado Health Sciences Center  
4200 East 9th Avenue / Box B-163  
Denver, CO 80262

Contact: M Graham Ray (303) 372-5535  
OPEN 960918.

0000003607:

New England Medical Center  
750 Washington Street / NEMCH67  
Boston, MA 02111

Contact: Charlene Gaca (617) 636-8186  
OPEN 960916.

0000003594:

Harvard University / Massachusetts General Hospital  
55 Fruit Street / Gray 5  
Boston, MA 02114

Contact: Ellen Godfrey McCarthy (617) 726-5598  
OPEN 960916.

0000003608:

Beth Israel Medical Center  
First Avenue at 16th Street  
New York, NY 10003

Contact: Gwen Constantini (212) 420-4519  
OPEN 961021.

0000003606:  
University of Texas Medical Branch  
Route 0835 / 301 University Boulevard  
Galveston, TX 77555-0835  
Contact: Phyliss Galatas (409) 747-0241  
OPEN 960916.

\*\*\*\*\*

PROTOCOL NUMBER: FDA 232C.

TITLE: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled  
Study of the Efficacy and Safety of Adefovir Dipivoxil When  
Added to Standard Antiretroviral Therapy for the Treatment of  
HIV-Infected Patients With CD4 Cell Counts  $\geq 200/\text{mm}^3$ .

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV infection. 2. HIV RNA titer  $\geq 2500$  copies/ml (2.5 KEq/ml) plasma by branched DNA analysis within the past 2 weeks. 3. CD4 count  $\geq 200$  cells/mm<sup>3</sup> within the past month. 4. No new AIDS-defining event within the past 2 months. 5. Tolerated antiretroviral therapy for the past 2 months. NOTE: Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month.

PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. HIV infection with HIV RNA titer  $\geq 2500$  copies/ml (2.5 KEq/ml) plasma.
  2. CD4 count  $\geq 200$  cells/mm<sup>3</sup>.
  3. No new AIDS-defining event within the past 2 months.
  4. Life expectancy at least 1 year.
  5. Consent of parent or guardian if less than 18 years old.
  6. Tolerated antiretroviral therapy for the past 2 months.
- NOTE: Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month.

AGE: 13 Years - 99 Years.

SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Not pregnant. Negative pregnancy test within 14 days of study entry.  
Not breast-feeding. Abstinence or effective method of birth control / contraception including oral contraceptives during the study.

PRIOR MEDICATION:

Required: Antiretroviral therapy for at least the past 2 months.

#### CONCURRENT MEDICATION:

Required: Antiretroviral regimen other than study drug.

#### LABORATORY VALUES AT ENTRY

-----

HEMOGLOBIN:  $\geq 8$  g/dl. (without hematologic growth factors).

PLATELET COUNT:  $\geq 50000$  platelets/mm<sup>3</sup>.

CD4 (T4 CELL) COUNT:  $\geq 200$  cells/mm<sup>3</sup>. ( 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus ).

SGOT (AST):  $\leq 3 \times$  ULN. (ULN = upper limit of normal).

SGPT (ALT):  $\leq 3 \times$  ULN.

CREATININE:  $\leq 1.5 \times$  ULN.

KARNOFSKY:  $\geq 80$ .

OTHER LABORATORY VALUES: Absolute neutrophils  $\geq 750$  cells/mm<sup>3</sup>. Serum amylase  $\leq 1.5 \times$  ULN ( if serum amylase  $> 1.5 \times$  ULN, then pancreatic amylase or lipase  $< 1.5 \times$  ULN may be substituted).

#### PATIENT EXCLUSION CRITERIA

-----

AGE: 01 Days - 12 Years.

#### REPRODUCTIVE SPECIFICATION:

Pregnant. Positive pregnancy test within 14 days of study entry.

Breast-feeding. No abstinence or no agreement to use effective method of birth control / contraception during the study.

#### RISK BEHAVIOR:

Current alcohol or substance abuse that would interfere with compliance.

#### PRIOR MEDICATION:

Excluded:

1. Parenteral antibiotic or antiviral therapy for another active, serious infection within the past 2 weeks.
2. Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons within the past month.
3. Systemic therapy for KS within the past month.

#### CONCURRENT MEDICATION:

Excluded:

1. Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons.
2. Isoniazid.
3. Rifampin.
4. Investigational agents (unless approved by sponsor).
5. Systemic chemotherapeutic agents.

#### CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:

1. Active, serious infections other than HIV that require parenteral antibiotic or antiviral therapy.
2. Gastrointestinal malabsorption syndrome or chronic nausea or vomiting that would preclude oral medication.
3. Malignancy other than Kaposi's sarcoma or basal cell carcinoma.

#### GENERIC DRUG NAME

-----

Drug 1: Adefovir dipivoxil. Antiretroviral.

#### DRUG COMPANIES

-----

Drug 1: Gilead Sciences Incorporated  
353 Lakeside Drive  
Foster City, CA 94404  
Contact: Dr Jay Toole (415) 573-4751.

#### END POINT

-----

Drug efficacy, toxicity.

#### PARTICIPATING UNITS

-----

0000003593:  
University of Alabama at Birmingham  
908 20th Street South  
Birmingham, AL 35294-2041  
Contact: Betty McCulloch (205) 975-7925  
OPEN 960808.

0000002310:  
Harbor - UCLA Medical Center  
1124 West Carson Street / Lab E2  
Torrance, CA 90502  
Contact: Sally Krueger (310) 533-3848  
OPEN 960808.

0000003567:  
Kraus Medical Partners  
5901 West Olympic Blvd / Suite 310  
Los Angeles, CA 90509  
Contact: Uni Kim (213) 930-2324  
OPEN 960808.

0000003571:  
Pacific Oaks Research  
4940 Van Nuys Boulevard / 2nd Floor  
Sherman Oaks, CA 91403  
Contact: Sindy Kim (818) 906-6279  
OPEN 960808.

0000003568:  
San Francisco General Hospital  
995 Potrero Avenue / Building 80 / Ward 84  
San Francisco, CA 94115  
Contact: Anna Smith (415) 476-4082 X 84098  
OPEN 960808.

0000003572:  
San Mateo County Medical Center / San Mateo County AIDS Prog  
3700 Edison Street  
San Mateo, CA 94403  
Contact: Brian Camp (415) 364-6563  
OPEN 960808.

0000003151:  
East Bay AIDS Center  
3031 Telegraph Avenue / Suite 235  
Berkeley, CA 94705  
Contact: Nancy Orcutt (510) 204-1291  
OPEN 960808.

0000002575:  
Santa Clara Valley Medical Center  
751 South Bascom Avenue  
San Jose, CA 95128-2699  
Contact: Carol Kane (408) 885-4316  
Contact: Dr Carol Kemper (assoc dir) (408) 885-4300  
OPEN 960808.

0000003509:  
Georgetown University Medical Center  
3800 Reservoir Road NW / Kober - Cogan Building / Suite 110  
Washington, DC 20007  
Contact: Irene Scanlon RN (202) 687-1079  
Contact: (202) 687-6845  
OPEN 960808.

0000003570:  
Institute for Clinical Research  
50 Irving Street NW 151-B / VA Medical Center  
Washington, DC 20422  
Contact: Peg Lankford (202) 745-8000 X 5007  
Contact: Donna Mills  
OPEN 960808.

0000002252:  
University of South Florida

5471 4th Street South  
St Petersburg, FL 33705  
Contact: Pat Seeley (813) 974-3163  
OPEN 960808.

0000003603:  
AIDS Research Consortium of Atlanta  
131 Ponce de Leon Avenue / Suite 130  
Atlanta, GA 30308  
Contact: Harriotte Bohn (404) 876-2317  
OPEN 960912.

0000003577:  
Chicago Center / Clinical Research  
515 North State Street / Suite 2700  
Chicago, IL 60610  
Contact: Julie Frowick (312) 494-2206  
OPEN 960808.

0000002777:  
Northwestern University  
303 East Superior Street / Passavant Pavilion / Room 828  
Chicago, IL 60611  
Contact: Pam Donath (312) 908-0949  
OPEN 960808.

0000003575:  
Tulane University / Tulane/LSU Clinical Trials Unit  
1430 Tulane Avenue  
New Orleans, LA 70122  
Contact: Dawn Morgado (504) 587-7316  
OPEN 960808.

0000003594:  
Harvard University / Massachusetts General Hospital  
55 Fruit Street / Gray 5  
Boston, MA 02114  
Contact: Ellen Godfrey McCarthy (617) 726-5598  
OPEN 960808.

0000003574:  
Wayne State University / University Health Center  
Pod 6F 4201 Saint Antoine  
Detroit, MI 48201  
Contact: Helen Dries (313) 993-0926  
OPEN 960808.

0000002129:  
Carolinas Medical Center  
1000 Blythe Boulevard  
Charlotte, NC 28204  
Contact: Dr James Horton (704) 355-5292 X 3165  
Contact: Joan Connell (704) 355-5292  
OPEN 960808.

0000003579:

Saint Vincent's Medical Center  
412 6th Avenue / Room 401  
New York, NY 10011

Contact: M George (212) 228-8000  
OPEN 960808.

0000003602:

Saint Vincent's Medical Center  
412 6th Avenue / Room 401  
New York, NY 10011

Contact: Mary Katherine George (212) 228-8000  
OPEN 960912.

0000003578:

Albany Medical College / Clinical Pharmacy Studies  
Unit A-142 / 47 New Scotland Avenue  
Albany, NY 12208

Contact: Carol MacDonald (205) 975-6323  
OPEN 960808.

0000003601:

The Research and Education Group  
2701 NW Vaughn / Suite 840  
Portland, OR 97210-5311

Contact: Norma Martinez (503) 229-8428  
OPEN 960912.

0000003580:

Vanderbilt University Medical Center  
Medical Arts Building / 1211 Twenty-first Ave S / Ste 539  
Nashville, TN 37212

Contact: D Haas (615) 936-1174  
OPEN 960808.

0000003573:

Dallas VA Medical Center  
4500 Lancaster Road  
Dallas, TX 75216

Contact: Sherrie Norris (214) 648-3877  
OPEN 960808.

0000003569:

Houston Clinical Research Network  
1200 Binz / Suite 120  
Houston, TX 77004

Contact: Barbara Griffin (713) 520-2000 X 211  
OPEN 960808.

0000003576:

University of Texas  
200 University Boulevard / Suite 518  
Galveston, TX 77555-0835

Contact: Phyllis Galatas (409) 747-0241  
OPEN 960808.

0000001480:  
University of Utah School of Medicine  
50 North Medical Drive / Room 4B 322  
Salt Lake City, UT 84132  
Contact: Susan Bracken (801) 581-4878  
OPEN 960808.

0000002960:  
University of Wisconsin  
600 Highland Avenue / H-6/368 CSC  
Madison, WI 53792  
Contact: Jeff Howells (608) 265-5729  
OPEN 960808.

\*\*\*\*\*

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 16:33:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <0119PIGLTLV40011G6@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Fri,  
20 Sep 1996 16:33:09 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119PIGIQF5S000V71@PMDF.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 16:33:05 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119PIDW690C00007L@STORM.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 16:30:58 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id QAA26910; Fri,  
20 Sep 1996 16:33:05 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:20-SEP-1996 10:00:00.00

SUBJECT: MMWR 09/20/96: Satellite Videoconference/Erratum

TO: levi\_j ( levi\_j@AI@CD ) (WHO)

READ:23-SEP-1996 08:57:19.79

TEXT:

MORBIDITY AND MORTALITY WEEKLY REPORT

\*\*\*\*\*

Centers for Disease Control and Prevention

September 20, 1996

Vol. 45, No. 37

Notice to Readers

Satellite Videoconference on HIV/AIDS Prevention for Teens

"HIV/AIDS Prevention for Teens," a satellite videoconference, will be broadcast live to sites nationwide from the Massachusetts Corporation for Educational Telecommunications (MCET) through a cooperative agreement with CDC on December 12, 1996, from 3 p.m. to 4:30 p.m. eastern standard time. The course is aimed at teachers of students in grades 6-12, health educators, community leaders, counselors, and administrators. Participants will receive an overview of HIV/AIDS education and guidance in targeting prevention strategies for youth.

Additional information, registration forms, and coordinates for down-link sites are available from MCET, telephone (800) 556-4376. The deadline to register down-link sites and participants is November 5.

Erratum: Vol. 45, No. 34

In the article "HIV Testing Among Women Aged 18-44 Years--United States, 1991 and 1993" in the third paragraph, on page 734, the first sentence should read, "From 1991 to 1993, the proportion of women aged 18-44 years who had ever been tested for HIV increased 69% (from 18.8% to 31.8%) (Table 1)."

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:20-SEP-1996 10:01:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <01I9P4QJGC9S000T2M@PMD.F.EOP.GOV> for levi\_j@a1.eop.gov; Fri,  
20 Sep 1996 10:00:18 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMD.F V5.0-4 #6879) id <01I9P4QF6K00000LHA@PMD.F.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 10:00:12 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMD.F V5.0-7 #6879) id <01I9P4NSF5FY00007L@STORM.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 09:58:04 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA08376; Fri,  
20 Sep 1996 10:00:12 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:20-SEP-1996 10:01:19.96

SUBJECT: URGENT

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:20-SEP-1996 10:28:38.13

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:20-SEP-1996 10:03:38.72

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:23-SEP-1996 09:30:26.87

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:20-SEP-1996 10:59:43.13

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:20-SEP-1996 11:34:55.19

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:20-SEP-1996 10:30:20.25

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:20-SEP-1996 10:48:10.87

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ:23-SEP-1996 16:18:48.01

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:20-SEP-1996 11:33:37.12

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:21-SEP-1996 14:44:06.23

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:20-SEP-1996 10:08:01.89

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:20-SEP-1996 10:01:35.57

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:20-SEP-1996 10:19:06.52

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:20-SEP-1996 10:22:10.28

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:20-SEP-1996 10:01:52.57

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:20-SEP-1996 10:03:16.66

TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S ) (OPD)  
READ:20-SEP-1996 10:02:25.29

TEXT:  
please send me your weekly ASAP this morning if you're doing one. If not,  
please let me know. Right now I have stuff from ONE person. Thanks.

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: aidsnews@cdcnac.aspensys.com@INET@EOPMRX

CREATION DATE/TIME:23-SEP-1996 10:25:00.00

SUBJECT: CDC AIDS Daily Summary 09/23/96

TO: levi\_j ( levi\_j@A1@CD ) (WHO)

READ:23-SEP-1996 10:36:11.05

TEXT:

AIDS Daily Summary  
September 23, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"D.C. to Use Needles in AIDS Fight"

"FDA Guidelines Aimed at Minimizing Risks in Animal-to-Human Transplants"

"Dental Worker With AIDS Virus Is Sent Home"

"Denial and Taboo Blind India to the Horror of its AIDS Scourge"

"AIDS Healthcare Foundation to Close its Oldest Hospice"

"Scabies Reported at Johns Hopkins"

"Little Room for Recovery"

"Catholic U. Ejects 'Angels'"

"City Schools Still Screen Illegally for AIDS"

"Ritonavir Plus Saquinavir: Two Trials With Different Results"

\*\*\*\*\*

"D.C. to Use Needles in AIDS Fight"

Washington Post (09/23/96) P. B1; Goldstein, Amy

The first large-scale needle exchange program in the Washington, D.C. area will begin next month, city officials announced Friday. Under the plan, the KOBA Institute--a nonprofit consortium that includes the Whitman-Walker Clinic--will distribute more than 100,000 sterile syringes over the next year in Washington communities where drug use is rampant and AIDS is on the rise. A short experimental program was attempted four years ago, but it was used by only 33 of the city's estimated 16,000 drug users. Increasing concern over the spread of HIV has overcome resistance to the controversial strategy. A total of 8,700 city residents have been diagnosed with AIDS since the early 1980s, and 5,000 people have died of

the disease. As many as 17,000 are infected with HIV, and the virus is spreading rapidly among intravenous drug users and their sexual partners and children.

#### "FDA Guidelines Aimed at Minimizing Risks in Animal-to-Human Transplants"

Wall Street Journal (09/23/96) P. B10H; McGinley, Laurie

The Food and Drug Administration announced on Friday guidelines for animal-to-human transplants, but scientists are still daunted by the medical problems involved in such procedures. The guidelines are intended to minimize the risks to public health while encouraging more research on the transplants. One well-known example of an animal-to-human transplant, or xenotransplant, took place in 1995 when AIDS patient Jeff Getty received bone marrow from a baboon. Under the new guidelines, researchers are advised to take safety measures to minimize the risk of cross-species transmission of diseases; select experts in infectious disease and animal health; receive approval from local hospital review boards; and monitor patients after the transplants for animal organisms.

#### "Dental Worker With AIDS Virus Is Sent Home"

USA Today (09/23/96) P. 8A; Komarow, Steven

A U.S. Army dental technician who has treated 1,100 soldiers and family members, including 300 in Bosnia, was sent back to the United States after he tested positive for HIV. An Army representative said sterilization procedures make the risk of infection very small, but patients are being offered counseling and testing if requested.

#### "Denial and Taboo Blind India to the Horror of its AIDS Scourge"

New York Times (09/22/96) P. 1; Burns, John F.

The threat of AIDS is especially strong in India, where prostitution and unprotected sex are common and prevention programs are mostly ineffective. United Nations AIDS agencies have estimated that one million Indians will have AIDS by 1999, and as many as 10 million will be infected with HIV. Of all projected infections worldwide, 25 percent will be in India. Indian officials have estimated that as many as 20 million, or even 50 million, Indians will be infected by 2000, and that there will be more AIDS patients than hospital beds. The government's AIDS program has been criticized for being unorganized, under-funded, and burdened by bureaucracy in a country where there are now some 970 million people.

#### "AIDS Healthcare Foundation to Close its Oldest Hospice"

Los Angeles Times--Washington Edition (09/23/96) P. B4

Financial difficulties and changes in AIDS care are forcing the AIDS Healthcare Foundation of Los Angeles to close its oldest hospice. The Chris Brownlie House, which opened in 1988, will shut its doors this week. Foundation President Michael Weinstein said the demand for hospice care has decreased due to advances in drug treatment. The rising costs of such treatments have also been cited as reasons for the organization's financial problems.

"Scabies Reported at Johns Hopkins"

Washington Times (09/23/96) P. C6

Outbreaks of scabies at Johns Hopkins Hospital in Baltimore prompted officials to shut down an AIDS outpatient clinic over the weekend and attempt to locate and check 150 patients who visited the HIV ward in the past three months. The skin infection, caused by a burrowing mite, was contracted by at least two dozen hospital workers during two outbreaks.

"Little Room for Recovery"

Washington Post (09/23/96) P. A1; Goldstein, Amy

Publicly funded treatment programs for drug addicts and alcoholics in Washington, D.C., and neighboring Prince George's County, Md., are having to turn people seeking help away because of reduced local funding. In Washington, D.C., local spending on treatment is almost one-third lower than 1992 levels. In Prince George's County, substance abuse appropriations have dropped from \$2 million in 1990 to \$180,000 this year. Programs in other area counties have also had to make changes. In Anne Arundel County, Md., for example, the only county money used for outpatient treatment funds methadone therapy because heroin use is increasing and contributing to a higher AIDS rate. Still, a few local initiatives are helping the cause, aided in part by a \$16.5 million federal grant that has been awarded to area programs to treat low-income women with drug addictions who are pregnant, homeless, or infected with HIV or tuberculosis.

"Catholic U. Ejects 'Angels'"

Washington Post (09/21/96) P. C1; Swisher, Kara

A production of the Pulitzer Prize-winning play "Angels in America," about AIDS and homophobia, is under attack by Catholic University administration. The play was approved earlier this year by the university's drama department, but the administration has banned advertising for the play and ordered that it move to an off-campus venue. The administration noted that it "reserves the right to determine the appropriateness of public presentations to ensure consistency with the university's mission."

"City Schools Still Screen Illegally for AIDS"

Crain's Chicago Business (09/09/96) Vol. 19, No. 37, P. 3; Hinz, Greg

The Chicago Public School system continues to require individuals applying for teaching positions to reveal whether or not they have HIV, despite promising to delete the question from medical forms six months ago. The school system is also asking other potentially illegal, highly personal questions as part of its medical examination form for job applicants. The school system has called the questioning "an oversight" and "improper." However, a spokeswoman for Lambda Legal Defense, a New York-based gay rights law firm, suggests that the schools have a credibility problem, having agreed to remove the question from forms in March but not appearing "to have exerted a lot of energy to follow

through on what they promised." Two years ago, Chicago Mayor Richard M. Daley ordered the city agencies not to question job applicants about their HIV-status after the city had to pay \$90,000 in legal costs for testing police applicants for HIV.

"Ritonavir Plus Saquinavir: Two Trials With Different Results"  
AIDS Treatment News (09/06/96) No. 254, P. 5; Mascolini, Mark

Two trials testing the combination of the protease inhibitors ritonavir and saquinavir recently came to different conclusions, possibly explained by differences in trial size, drug dosage, and disease stage of the participants. Studies have suggested that ritonavir greatly increases blood levels of saquinavir, making a combination of the two especially attractive. One trial of 63 individuals, led by Dr. William Cameron of the University of Ottawa, found that two different doses of the drugs decreased viral load up to 99 percent and increased CD4 counts by 80 to 100 points. However, a smaller, nine-person study led by Dr. Bernard Hirschel of the University Hospital of Geneva, showed that viral load was reduced by at least 90 percent, though it quickly rebounded in some patients. The trials suggest that resistance to the drugs does not develop immediately, although it could emerge later. Researchers are now attempting to find the proper dosing strategy--one that is strong enough to suppress viral replication and prevent resistance while being mild enough to be tolerated.

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:23-SEP-1996 10:25:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <0119TCH2CIZ4001RLJ@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Mon,  
23 Sep 1996 10:24:53 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119TCGZ5UW0001S1S@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Mon, 23 Sep 1996 10:24:49 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119TCE3Y3IU00007L@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Mon, 23 Sep 1996 10:22:30 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA29229; Mon,  
23 Sep 1996 10:24:44 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 08:58:26.37

SUBJECT: actis

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:23-SEP-1996 14:20:42.10

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 15:48:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: New Information from ACTIS 09/19/96 (2 of 2)

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

New Information from ACTIS

September 19, 1996

2 of 2

PROTOCOL NUMBER: FDA 256A.

TITLE: A Multicenter Phase II/III, Placebo-Controlled Study of SNX-111  
Administered Intrathecally to Cancer and AIDS Patients With  
Chronic Pain.

PHASE: Phase II / Phase III.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. Chronic pain related to HIV or cancer. 2. Unsatisfactory response to opioid therapy (intolerable side effects or inadequate pain relief).

#### PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. Chronic pain related to HIV or cancer.
2. Unsatisfactory response to prior opioid therapy.
3. Life expectancy > 3 months (or 1 month if an infusion pump is in place).

AGE: 18 Years - 99 Years.

SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Not pregnant. Not breast-feeding.

CONCURRENT MEDICATION:

Allowed: Rescue analgesia.

LABORATORY VALUES AT ENTRY

-----

CD4 (T4 CELL) COUNT: Unspecified cells/mm3.

PATIENT EXCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients with the following prior conditions are excluded:

History of heart disease, heart failure, or asthma.

AGE: 01 Days - 17 Years.

REPRODUCTIVE SPECIFICATION:

Pregnant. Breast-feeding.

CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:

Signs of sepsis or inadequately treated infection.

GENERIC DRUG NAME

-----

Drug 1: SNX-111. Calcium Channel Blocker.

DRUG COMPANIES

-----

Drug 1: Neurex Corporation

3760 Haven Avenue

Menlo Park, CA 94025

Contact: Unspecified

(415) 853-1500.

PARTICIPATING UNITS

-----

0000003563:

Clinical Solutions

103 Carnegie Center / Suite 106

Princeton, NJ 08540  
Contact: Unspecified (800) 577-8839 X 92  
OPEN / USA accrual (Call for study sites) 960604.

\*\*\*\*\*

PROTOCOL NUMBER: FDA 257A.

TITLE: Study of the Safety and Effects of Two Doses of SPC3, Administered Daily Intravenously in HIV-1 Seropositive Patients. (FDA DISCLAIMER: The FDA encourages the inclusion of females of childbearing potential in study protocols, but the sponsor of this protocol specifically excludes females of childbearing potential from this study and includes only females who are sterile. Any questions about these inclusion/exclusion criteria should be directed to the study's contact person.)

PHASE: Phase I / Phase II.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV seropositive for at least 6 months. 2. CD4  $\geq$  100 cells/mm<sup>3</sup>. 3. HIV RNA PCR (Amplicor) > 10000 copies/ml. 4. No significant active opportunistic infection or tumor at study entry.

PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. HIV seropositive for at least 6 months.
2. CD4  $\geq$  100 cells/mm<sup>3</sup>.
3. HIV RNA PCR (Amplicor) > 10000 copies/ml.
4. No significant active opportunistic infection or tumor at study entry.

FDA DISCLAIMER: The FDA encourages the inclusion of females of childbearing potential in study protocols, but the sponsor of this protocol specifically excludes females of childbearing potential from this study and includes only females who are sterile. Any questions about these inclusion/exclusion criteria should be directed to the study's contact person.

AGE: 18 Years - 65 Years.

SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Postmenopausal or permanently sterile because of tubal ligation, hysterectomy, or oophorectomy. Not breast-feeding.

PRIOR MEDICATION:

Allowed: Prior antiretrovirals.

#### CONCURRENT MEDICATION:

Allowed: Antiretrovirals provided regimen has been stable for at least 6 weeks prior to study screening.

#### LABORATORY VALUES AT ENTRY

-----

HEMOGLOBIN: > 10 g/dl.

CD4 (T4 CELL) COUNT:  $\geq 100$  cells/mm<sup>3</sup>. ( 100 - 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus ).

BILIRUBIN:  $\leq 3 \times$  ULN mg/dl. (ULN = upper limit of normal).

SGOT (AST):  $\leq 3 \times$  ULN.

SGPT (ALT):  $\leq 3 \times$  ULN.

CREATININE:  $\leq 1.6$  mg/dl.

KARNOFSKY: > 70.

OTHER LABORATORY VALUES: Neutrophils  $\geq 500$  cells/mm<sup>3</sup>.

#### PATIENT EXCLUSION CRITERIA

-----

##### SPECIFICATION CRITERIA:

Patients with the following prior condition are excluded:  
History of relevant drug hypersensitivity.

AGE: 01 Days - 17 Years. 66 Years - 99 Years.

##### REPRODUCTIVE SPECIFICATION:

Future reproduction. Breast-feeding.

##### PRIOR MEDICATION:

Excluded: Investigational drug within the past 4 weeks.

##### CONCURRENT MEDICATION:

Excluded: Any drug that may interact with SPC3 (e.g., suramin).

##### CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following conditions are excluded:  
Inability to communicate with investigator or deemed likely to be noncompliant on study.

#### GENERIC DRUG NAME

-----

Drug 1: Synthetic Peptide Construction 3. Antiretroviral.

#### DRUG COMPANIES

-----

Drug 1: Columbia Research Laboratories Incorporated  
100 North Village Avenue / Suite 32  
Rockville Centre, NY 11570  
Contact: Dr Howard Levine (516) 766-2660.

#### PARTICIPATING UNITS

0000003590:  
Roger Williams Medical Center  
825 Chalkstone Avenue  
Providence, RI 02908  
Contact: Grace Acetta (401) 456-2532  
OPEN 960822.

\*\*\*\*\*

#### DRUG RECORDS

Accession Number:  
DRG-0250.  
Generic Name:  
SNX-111 (FDA 256A).  
Protocol Number(s):  
Open FDA 256A  
Alias/Trade Name:  
SNX 111 (MeSH). omega-Conopeptide MVIIA (MeSH). omega-Conotoxin MVIIA,  
Conus magus (MeSH).  
Chemical Abstract Name:  
omega-Conotoxin MVIIA (CHEMLINE).  
CAS Registry Number:  
107452-89-1 (CHEMLINE).  
Drug Company(ies):  
Neurex Corporation  
3760 Haven Avenue  
Menlo Park, CA 94025  
Contact: Unspecified (415) 853-1500.  
Therapeutic Classification:  
Calcium Channel Blocker (CHEMLINE).  
Drug Description:  
Synthetic homologue of omega-conopeptide.  
(J Pharmacol Exp Ther 1995 Aug;274(2) p 666-72)  
Pharmacology:  
MODE OF ACTION: Relieves pain by interfering with the  
neurotransmission of pain impulses. Blocks neuronal N-type  
voltage-sensitive calcium channels.  
(FDA 256A; J Pharmacol Exp Ther 1995 Aug;274(2) p 666-72)  
Contraindications:  
Contraindicated in pregnant and nursing women.  
(FDA 256A)

Mode of Delivery:

Intrathecal. (FDA 256A)

AIDS-Related Uses:

Pain related to HIV. (FDA 256A)

Other Uses:

Pain related to cancer.  
(FDA 256A)

Bibliographic References:

95363679. Xiao WH, Bennett GJ. Synthetic omega-conopeptides applied to the site of nerve injury suppress neuropathic pains in rats. J Pharmacol Exp Ther 1995 Aug;274(2):666-72.

95315196. Nadasdi L, Yamashiro D, Chung D, Tarczy-Hornoch K, Adriaenssens P, Ramachandran J. Structure-activity analysis of a Conus peptide blocker of N-type neuronal calcium channels. Biochemistry 1995 Jun 27;34(25):8076-81.

95126938. Kim JI, Takahashi M, Ohtake A, Wakamiya A, Sato K. Tyr13 is essential for the activity of omega-conotoxin MVIIA and GVIA, specific N-type calcium channel blockers. Biochem Biophys Res Commun 1995 Jan 17;206(2):449-54.

95067173. Hovda DA, Fu K, Badie, H, Samii A, Pinanong P, Becker DP. Administration of an omega-conopeptide one hour following traumatic brain injury reduces 45calcium accumulation. Acta Neurochir Suppl (Wien) 1994;60:521-3.

\*\*\*\*\*

Accession Number:

DRG-0251.

Generic Name:

Synthetic Peptide Construction 3 (FDA 257A).

Protocol Number(s):

Open FDA 257A

Alias/Trade Name:

SPC3 (FDA 257A). SPC3 peptide (MeSH).

Drug Company(ies):

Columbia Research Laboratories Incorporated  
100 North Village Avenue / Suite 32  
Rockville Centre, NY 11570  
Contact: Dr Howard Levine (516) 766-2660.

Therapeutic Classification:

Antiretroviral (FDA 257A).

Drug Description:

Synthetic multibranched peptide containing eight HIV-1 gp120 V3 loop GPGRF motifs.  
(Biochemistry 1995 Jul 4;34(26) p 8294-8)

Pharmacology:

MODE OF ACTION: Data suggest that SPC3 prevents HIV-1 attachment to the surface of CD4- cells that express galactosylceramide, an alternative receptor for HIV-1 gp120. In CD4+ lymphocytes, SPC3

interferes with a post-binding step necessary for virus entry into the cell.

(Proc Natl Acad Sci USA 1995 May 23;92(11) p 4867-71)

Contraindications:

Contraindicated in women of reproductive potential.

(FDA 257A)

Mode of Delivery:

Intravenous. (FDA 257A)

AIDS-Related Uses:

HIV infection. (FDA 257A)

Bibliographic References:

MED/95281557. Yahi N, Fantini J, Baghdiguian S, Mabrouk K, Tamalet C, Rochat H, Van Rietschoten J, Sabatier JM. SPC3, a synthetic peptide derived from the V3 domain of human immunodeficiency virus type 1 (HIV-1) gp120, inhibits HIV-1 entry into CD4+ and CD4- cells by two distinct mechanisms. Proc Natl Acad Sci U S A. 1995 May 23;92(11):4867-71.

\*\*\*\*\*

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:20-SEP-1996 15:49:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <0119PGVYXEJK0011SU@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Fri,

20 Sep 1996 15:48:16 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119PGVWTBCG000VL3@PMDF.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 15:48:13 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119PGTBO1RG00007L@STORM.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 15:46:08 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id PAA20990; Fri,

20 Sep 1996 15:48:17 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 09:00:07.23

SUBJECT: daily news

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:09:34.55

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)  
READ:23-SEP-1996 14:12:15.56

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:27-SEP-1996 14:57:31.95

TEXT:

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:20-SEP-1996 17:30:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 09/20/96

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

AIDS Daily Summary  
September 20, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*

"Confidential AIDS Data Given to Paper"  
"Health Officials Are Urging a Focus on AIDS in Prisons"  
"Morrison Plans One More Fight Despite H.I.V.-Positive Status"  
"Rare, Deadly Germs Discovered Globally"  
"The Trades of the Tricks"  
"Disease Threat Arriving via Foreign Ships"  
"Tennessee Court Rules for Insurer in Failure to Disclose Case Involving HIV-Positive Male"

"Occupational Risks Associated With Tuberculosis Listed"

"Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection"

"HIV Patient Denied Hospital Admission"

\*\*\*\*\*

"Confidential AIDS Data Given to Paper"

Washington Post (09/20/96) P. A7

The Tampa Tribune was anonymously sent a copy of a confidential computer disk containing the names of 4,000 AIDS patients. The disk was mailed to the newspaper with a letter which said the disk was dropped outside a bar by a drunken public health worker who had showed the list to friends on a laptop computer. The writer also claimed to have made a copy of the disk. The newspaper reports that it gave a copy of the disk and letter to the Florida Department of Health and Rehabilitative Services, which is investigating the incident. The public health worker, one of three people with access to the information, has been placed on paid administrative leave. A state health department representative called the incident "probably about the worst thing that could happen in the AIDS program."

"Health Officials Are Urging a Focus on AIDS in Prisons"

Philadelphia Inquirer (09/20/96) P. A25; Vedantam, Shankar

The rate of AIDS in U.S. prisons is six times greater than the national average, federal researchers report, adding that about 22 million Americans enter and leave jails and prisons each year. Unsafe sex practices and needle sharing put inmates at high risk, and increase the chance that they will carry the virus with them when released. Researchers at the Centers for Disease Control and Prevention reported their findings Thursday in the American Journal of Public Health. They are supporting AIDS education for prisoners, and the distribution of condoms and clean needles in jails and prisons. Most correctional facilities are reluctant to provide prisoners with condoms and needles, however, because they see such practices as condoning activity they do not allow. Researchers and prison advocates say this position is unrealistic, and increases the risk of spreading HIV.

"Morrison Plans One More Fight Despite H.I.V.-Positive Status"

New York Times (09/20/96) P. B8; Roberts, Selena

Although boxer Tommy Morrison announced in February, after learning that he is infected with HIV, that he would "absolutely" not box again, he said Thursday that he wants to fight "one last time." Morrison was suspended from the sport in Nevada because he tested positive for the virus that causes AIDS, but some states do not screen boxers for HIV. If he can find an opponent, Morrison said he wants to schedule a fight to benefit his foundation, Knockout AIDS. He says he has been convinced by medical evidence that HIV cannot be spread in the ring. His promoter, Tony Holden, is not yet convinced of this, however, and says that, until he is, he will not promote such a match. Boxer Ross Puritty said that he is willing to fight Morrison "if the money is right."

### "Rare, Deadly Germs Discovered Globally"

USA Today (09/20/96) P. 12D; Manning, Anita

New germs, some deadly, are emerging all over the world, researchers from the Centers for Disease Control and Prevention report. Among the new microbes discussed at a meeting of the American Society for Microbiology, was hepatitis G, a new form of the virus. that appears to be transmitted in the blood but has not been linked to disease. The researchers also pointed to bartonella, discovered in 1990, as the cause of various illnesses in healthy people, but which can be fatal to people with compromised immunity. In AIDS patients, it causes an illness that mimics Kaposi's sarcoma. Dr. Jane E. Koehler says it is critical for doctors to recognize the difference, because the treatment is completely different.

### "The Trades of the Tricks"

Washington Post (09/19/96) P. C1; Bowles, Scott

Police say that escort services have become popular among white-collar johns in the Washington, D.C., area. Using cellular phones, voice mail systems, and computers to process credit-card payments, call girls in the region often operate as professionals through agencies that often escape prosecution. However, these women note that they still fear contracting HIV. While they usually demand that a condom be worn, they "still live scared that the next guy has AIDS. You just have to weigh the risk against how much money you make," said one call girl.

### "Disease Threat Arriving via Foreign Ships"

USA Today (09/19/96) P. 3A; Tyson, Rae

Foreign ships coming to the United States are carrying bacteria that cause cholera and other deadly diseases thought to have been eradicated here. More than 21 billion gallons of ballast water, carrying cholera, E. coli, botulism, salmonella, cryptosporidium, and hepatitis A, are dumped by the ships that enter U.S. waters each year. The bacteria infect shellfish which, when eaten raw, can infect humans. Congress is now considering implementing new ballast water regulations.

### "Tennessee Court Rules for Insurer in Failure to Disclose Case Involving HIV-Positive Male"

Reuters (09/19/96)

A life insurance company's decision that a man who did not reveal that he had HIV was not eligible for disability benefits was upheld by a Tennessee Court of Appeals. Krystof Krakowiak filed a lawsuit against the Paul Revere Life Insurance, claiming that his condition should not have been covered under the company's pre-existing conditions clause. The company held that AIDS is not a pre-existing condition, but rather an illness, and that the policy did not cover pre-existing illnesses.

### "Occupational Risks Associated With Tuberculosis Listed"

Reuters (09/19/96)

Inhalation therapists, lower-paid health care workers, and

funeral directors are at increased risk for tuberculosis (TB) than the general population, federal researchers report. Matthew T. McKenna and colleagues at the Centers for Disease Control and Prevention say that people with the "most intensive interaction with patients with pulmonary disease" are at high risk for contracting TB. They suggest that the risk of TB in the community should be considered when implementing worksite TB control measures.

"Duration of the Survival Benefit of Zidovudine Therapy in HIV Infection"

Journal of the American Medical Association (09/11/96) Vol. 276, No. 10, P. 762; Moore, Richard D.

While zidovudine is known to provide a survival benefit for advanced AIDS patients, the length of time of this benefit is not known. However, researchers at the Johns Hopkins University School of Medicine now report in the Archives of Internal Medicine that the survival advantage lasts between one and two years. They made the estimate based on data from nearly 400 HIV-infected patients who were followed for three years. Compared to no treatment, a significant benefit from zidovudine was found during the first year of therapy. A diminishing benefit was found, however, at one to two years.

"HIV Patient Denied Hospital Admission"

American Medical News (09/09/96) Vol. 39, No. 34, P. 30

A federal trial court ruled that an Ohio hospital violated the Americans with Disabilities Act when it refused to admit an HIV-positive patient. The patient was taken to the emergency room after having an adverse reaction to a new medication. The attending physician determined that the patient had to be admitted, but the hospital's admitting physician denied the patient's admission. The patient was transferred to a medical college hospital, where the staff determined that he was having a simple, but severe, allergic reaction to his medication. The patient sued the first hospital and the admitting physician for violating the ADA, the Federal Rehabilitation Act, and the Emergency Medical Treatment and Active Labor Act. The trial court ruled against the hospital and the physician on the ADA claim only. The patient was not entitled to damages, but the hospital was enjoined from further violations of the ADA and ordered to post signs to inform HIV-infected patients of their protection from discrimination under the ADA.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:20-SEP-1996 17:31:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <01I9PKGD7968000UWA@PMDF.EOP.GOV> for levi\_j@al.eop.gov; Fri,  
20 Sep 1996 17:30:16 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <01I9PKG9HAN4000VOT@PMDF.EOP.GOV> for  
levi\_j@al.eop.gov; Fri, 20 Sep 1996 17:30:08 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <01I9PKDMC86A00007L@STORM.EOP.GOV> for  
levi\_j@al.eop.gov; Fri, 20 Sep 1996 17:28:00 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id RAA03251; Fri,  
20 Sep 1996 17:30:09 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Ursula Sanville ( SANVILLE\_U ) (OPD)

CREATION DATE/TIME:23-SEP-1996 12:11:52.64

SUBJECT: RE: scheduling model

TO: Jeffrey Levi ( LEVI\_J ) (WHO)

READ:23-SEP-1996 12:12:40.23

TEXT:

thanks

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 08:57:51.39

SUBJECT: adolescents conference

TO: Patsy Fleming ( FLEMING\_P ) (WHO)

READ:24-SEP-1996 14:06:47.42

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:23-SEP-1996 10:00:58.74

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)

READ:24-SEP-1996 13:13:00.25

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 10:00:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: MMWR 09/20/96: Satellite Videoconferece/Erratum

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

MORBIDITY AND MORTALITY WEEKLY REPORT

\*\*\*\*\*

Centers for Disease Control and Prevention

September 20, 1996

Vol. 45, No. 37

Notice to Readers

Satellite Videoconference on HIV/AIDS Prevention for Teens

"HIV/AIDS Prevention for Teens," a satellite videoconference, will be broadcast live to sites nationwide from the Massachusetts Corporation for Educational Telecommunications (MCET) through a cooperative agreement with CDC on December 12, 1996, from 3 p.m. to 4:30 p.m. eastern standard time. The course is aimed at teachers of students in grades 6-12, health educators, community leaders, counselors, and administrators. Participants will receive an overview of HIV/AIDS education and guidance in targeting prevention strategies for youth.

Additional information, registration forms, and coordinates for down-link sites are available from MCET, telephone (800) 556-4376. The deadline to register down-link sites and participants

is November 5.

Erratum: Vol. 45, No. 34

In the article "HIV Testing Among Women Aged 18-44 Years--United States, 1991 and 1993" in the third paragraph, on page 734, the first sentence should read, "From 1991 to 1993, the proportion of women aged 18-44 years who had ever been tested for HIV increased 69% (from 18.8% to 31.8%) (Table 1)."

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:20-SEP-1996 10:01:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <0119P4QJGC9S000T2M@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Fri,  
20 Sep 1996 10:00:18 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119P4QF6K00000LHA@PMDF.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 10:00:12 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119P4NSF5FY00007L@STORM.EOP.GOV> for  
levi\_j@a1.eop.gov; Fri, 20 Sep 1996 09:58:04 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA08376; Fri,  
20 Sep 1996 10:00:12 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 10:31:06.69

SUBJECT: daily news

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:10:00.61

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)  
READ:23-SEP-1996 14:08:06.72

TO: Lahoma Romocki ( ROMOCKI\_L ) (OPD)  
READ:23-SEP-1996 14:05:25.85

TEXT:

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:23-SEP-1996 10:24:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: CDC AIDS Daily Summary 09/23/96

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

AIDS Daily Summary  
September 23, 1996

The Centers for Disease Control and Prevention (CDC) National AIDS Clearinghouse makes available the following information as a public service only. Providing this information does not constitute endorsement by the CDC, the CDC National AIDS Clearinghouse, or any other organization. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC National AIDS Clearinghouse should be cited as the source of this information. Copyright 1996, Information, Inc., Bethesda, MD

\*\*\*\*\*  
"D.C. to Use Needles in AIDS Fight"  
"FDA Guidelines Aimed at Minimizing Risks in Animal-to-Human Transplants"  
"Dental Worker With AIDS Virus Is Sent Home"  
"Denial and Taboo Blind India to the Horror of its AIDS Scourge"  
"AIDS Healthcare Foundation to Close its Oldest Hospice"  
"Scabies Reported at Johns Hopkins"  
"Little Room for Recovery"

"Catholic U. Ejects 'Angels'"

"City Schools Still Screen Illegally for AIDS"

"Ritonavir Plus Saquinavir: Two Trials With Different Results"

\*\*\*\*\*

"D.C. to Use Needles in AIDS Fight"

Washington Post (09/23/96) P. B1; Goldstein, Amy

The first large-scale needle exchange program in the Washington, D.C. area will begin next month, city officials announced Friday. Under the plan, the KOBA Institute--a nonprofit consortium that includes the Whitman-Walker Clinic--will distribute more than 100,000 sterile syringes over the next year in Washington communities where drug use is rampant and AIDS is on the rise. A short experimental program was attempted four years ago, but it was used by only 33 of the city's estimated 16,000 drug users. Increasing concern over the spread of HIV has overcome resistance to the controversial strategy. A total of 8,700 city residents have been diagnosed with AIDS since the early 1980s, and 5,000 people have died of the disease. As many as 17,000 are infected with HIV, and the virus is spreading rapidly among intravenous drug users and their sexual partners and children.

"FDA Guidelines Aimed at Minimizing Risks in Animal-to-Human Transplants"

Wall Street Journal (09/23/96) P. B10H; McGinley, Laurie

The Food and Drug Administration announced on Friday guidelines for animal-to-human transplants, but scientists are still daunted by the medical problems involved in such procedures. The guidelines are intended to minimize the risks to public health while encouraging more research on the transplants. One well-known example of an animal-to-human transplant, or xenotransplant, took place in 1995 when AIDS patient Jeff Getty received bone marrow from a baboon. Under the new guidelines, researchers are advised to take safety measures to minimize the risk of cross-species transmission of diseases; select experts in infectious disease and animal health; receive approval from local hospital review boards; and monitor patients after the transplants for animal organisms.

"Dental Worker With AIDS Virus Is Sent Home"

USA Today (09/23/96) P. 8A; Komarow, Steven

A U.S. Army dental technician who has treated 1,100 soldiers and family members, including 300 in Bosnia, was sent back to the United States after he tested positive for HIV. An Army representative said sterilization procedures make the risk of infection very small, but patients are being offered counseling and testing if requested.

"Denial and Taboo Blind India to the Horror of its AIDS Scourge"

New York Times (09/22/96) P. 1; Burns, John F.

The threat of AIDS is especially strong in India, where prostitution and unprotected sex are common and prevention programs are mostly ineffective. United Nations AIDS agencies

have estimated that one million Indians will have AIDS by 1999, and as many as 10 million will be infected with HIV. Of all projected infections worldwide, 25 percent will be in India. Indian officials have estimated that as many as 20 million, or even 50 million, Indians will be infected by 2000, and that there will be more AIDS patients than hospital beds. The government's AIDS program has been criticized for being unorganized, under-funded, and burdened by bureaucracy in a country where there are now some 970 million people.

"AIDS Healthcare Foundation to Close its Oldest Hospice"  
Los Angeles Times--Washington Edition (09/23/96) P. B4

Financial difficulties and changes in AIDS care are forcing the AIDS Healthcare Foundation of Los Angeles to close its oldest hospice. The Chris Brownlie House, which opened in 1988, will shut its doors this week. Foundation President Michael Weinstein said the demand for hospice care has decreased due to advances in drug treatment. The rising costs of such treatments have also been cited as reasons for the organization's financial problems.

"Scabies Reported at Johns Hopkins"  
Washington Times (09/23/96) P. C6

Outbreaks of scabies at Johns Hopkins Hospital in Baltimore prompted officials to shut down an AIDS outpatient clinic over the weekend and attempt to locate and check 150 patients who visited the HIV ward in the past three months. The skin infection, caused by a burrowing mite, was contracted by at least two dozen hospital workers during two outbreaks.

"Little Room for Recovery"  
Washington Post (09/23/96) P. A1; Goldstein, Amy  
Publicly funded treatment programs for drug addicts and alcoholics in Washington, D.C., and neighboring Prince George's County, Md., are having to turn people seeking help away because of reduced local funding. In Washington, D.C., local spending on treatment is almost one-third lower than 1992 levels. In Prince George's County, substance abuse appropriations have dropped from \$2 million in 1990 to \$180,000 this year. Programs in other area counties have also had to make changes. In Anne Arundel County, Md., for example, the only county money used for outpatient treatment funds methadone therapy because heroin use is increasing and contributing to a higher AIDS rate. Still, a few local initiatives are helping the cause, aided in part by a \$16.5 million federal grant that has been awarded to area programs to treat low-income women with drug addictions who are pregnant, homeless, or infected with HIV or tuberculosis.

"Catholic U. Ejects 'Angels'"  
Washington Post (09/21/96) P. C1; Swisher, Kara  
A production of the Pulitzer Prize-winning play "Angels in America," about AIDS and homophobia, is under attack by Catholic University administration. The play was approved earlier this year by the university's drama department, but the administration has banned advertising for the play and ordered that it move to

an off-campus venue. The administration noted that it "reserves the right to determine the appropriateness of public presentations to ensure consistency with the university's mission."

"City Schools Still Screen Illegally for AIDS"

Crain's Chicago Business (09/09/96) Vol. 19, No. 37, P. 3; Hinz, Greg

The Chicago Public School system continues to require individuals applying for teaching positions to reveal whether or not they have HIV, despite promising to delete the question from medical forms six months ago. The school system is also asking other potentially illegal, highly personal questions as part of its medical examination form for job applicants. The school system has called the questioning "an oversight" and "improper." However, a spokeswoman for Lambda Legal Defense, a New York-based gay rights law firm, suggests that the schools have a credibility problem, having agreed to remove the question from forms in March but not appearing "to have exerted a lot of energy to follow through on what they promised." Two years ago, Chicago Mayor Richard M. Daley ordered the city agencies not to question job applicants about their HIV-status after the city had to pay \$90,000 in legal costs for testing police applicants for HIV.

"Ritonavir Plus Saquinavir: Two Trials With Different Results"  
AIDS Treatment News (09/06/96) No. 254, P. 5; Mascolini, Mark

Two trials testing the combination of the protease inhibitors ritonavir and saquinavir recently came to different conclusions, possibly explained by differences in trial size, drug dosage, and disease stage of the participants. Studies have suggested that ritonavir greatly increases blood levels of saquinavir, making a combination of the two especially attractive. One trial of 63 individuals, led by Dr. William Cameron of the University of Ottawa, found that two different doses of the drugs decreased viral load up to 99 percent and increased CD4 counts by 80 to 100 points. However, a smaller, nine-person study led by Dr. Bernard Hirschel of the University Hospital of Geneva, showed that viral load was reduced by at least 90 percent, though it quickly rebounded in some patients. The trials suggest that resistance to the drugs does not develop immediately, although it could emerge later. Researchers are now attempting to find the proper dosing strategy--one that is strong enough to suppress viral replication and prevent resistance while being mild enough to be tolerated.

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:23-SEP-1996 10:25:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDf V5.0-4 #6879)

id <01I9TCH2CIZ4001RLJ@PMDf.EOP.GOV> for levi\_j@al.eop.gov; Mon,

23 Sep 1996 10:24:53 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDf V5.0-4 #6879) id <01I9TCGZ5UW0001SIS@PMDf.EOP.GOV> for

levi\_j@al.eop.gov; Mon, 23 Sep 1996 10:24:49 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDf V5.0-7 #6879) id <01I9TCE3Y3IU00007L@STORM.EOP.GOV> for

levi\_j@al.eop.gov; Mon, 23 Sep 1996 10:22:30 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id KAA29229; Mon,

23 Sep 1996 10:24:44 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: aidsnews@cdcnac.aspensys.com

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 08:58:57.34

SUBJECT: actis

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:23-SEP-1996 14:17:53.34

TEXT:

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:20-SEP-1996 16:33:00.00

ATT BODYPART TYPE:E

ATT CREATOR: aidsnews

ATT SUBJECT: New Information from ACTIS 09/19/96 (1 of 2)

ATT TO: levi\_j ( levi\_j@A1@CD )

TEXT:

September 19, 1996

1 of 2

#### NEW INFORMATION FROM ACTIS

The AIDS Clinical Trials Information Service (ACTIS) is a central resource providing current information on federally and privately sponsored clinical trials for AIDS patients and others infected with HIV. This service is a Public Health Service project produced collaboratively by the Centers for Disease Control and Prevention, the Food and Drug Administration, the National Institute of Allergy and Infectious Diseases, and the National Library of Medicine. NAC ONLINE, the computerized information service of the CDC National AIDS Clearinghouse, will alert you to any new information collected by ACTIS.

Descriptions of four clinical trials and two drugs added to the ACTIS database are provided below.

For more information, call the ACTIS toll-free number to talk with a health specialist. On request, you can also obtain a printout of a customized search of the clinical trials databases. The information can also be accessed directly by subscribers through two online databases, AIDSTRIALS and AIDSDRUGS, available through the National Library of Medicine.

AIDS CLINICAL TRIALS INFORMATION SERVICE  
1-800-TRIALS-A

(1-800-874-2572)  
FAX: 1-301-738-6616  
TTY/TDD: 1-800-243-7012  
International Line: 1-301-217-0023

\*\*\*\*\*

PROTOCOL NUMBER: FDA 229D.

TITLE: A Randomized, Parallel Arm, Comparative, Open Label,  
Multicenter Study of the Activity and Safety of Two  
Formulations of Saquinavir in Combination With Other  
Antiretroviral Drugs.

PHASE: Phase II.

DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV  
infection. 2. Antiretroviral naive (i.e., less than 4 weeks of  
prior treatment) to at least one of the licensed nucleoside  
drugs. 3. No more than 2 weeks of prior treatment with a  
protease inhibitor.

PATIENT INCLUSION CRITERIA

-----

SPECIFICATION CRITERIA:

Patients must have:

1. HIV infection.
2. Antiretroviral naive (i.e., less than 4 weeks of prior treatment)  
to at least one of the licensed nucleoside drugs.
3. No more than 2 weeks of prior treatment with a protease inhibitor.

AGE: 13 Years - 99 Years.

SEX: M. F.

LABORATORY VALUES AT ENTRY

-----

CD4 (T4 CELL) COUNT: Unspecified cells/mm<sup>3</sup>.

PATIENT EXCLUSION CRITERIA

-----

AGE: 01 Days - 12 Years.

PRIOR MEDICATION:

Excluded:

1. More than 4 weeks of the prior nucleoside antiretroviral selected  
for the patient's regimen.
2. More than 2 weeks of any protease inhibitor.

CONCURRENT MEDICATION:

Excluded: Other protease inhibitors.

#### GENERIC DRUG NAME

-----

Drug 1: Saquinavir mesylate. Protease inhibitor.

Drug 2: Zidovudine. Antiretroviral.

Drug 3: Zalcitabine. Antiretroviral.

Drug 4: Didanosine. Antiretroviral.

Drug 5: Stavudine. Antiretroviral.

Drug 6: Lamivudine. Antiretroviral.

#### DRUG TRADE NAME

-----

Drug 1: Invirase.

Drug 2: Retrovir.

Drug 3: HIVID.

Drug 4: Videx.

Drug 5: Zerit.

Drug 6: Epivir.

#### DRUG COMPANIES

-----

Drug 1: Hoffmann - La Roche Incorporated

340 Kingsland Street

Nutley, NJ 07110-1199

Contact: Professional Services (800) 526-6367.

Drug 2: Glaxo Wellcome

5 Moore Drive / PO Box 13398

Research Triangle Park, NC 27709

Contact: Department of Consumer Affairs (800) 437-0992 X 7900.

Drug 3: Hoffmann - La Roche Incorporated

340 Kingsland Street

Nutley, NJ 07110-1199

Contact: Professional Services (800) 526-6367.

Drug 4: Bristol - Myers Squibb Company

2400 West Lloyd Expressway

Evansville, IN 47721-0001

Contact: Information (800) 662-7999.

Drug 5: Bristol - Myers Squibb Company

2400 West Lloyd Expressway

Evansville, IN 47721-0001

Contact: Information (800) 662-7999.

Drug 6: Glaxo Wellcome

5 Moore Drive / PO Box 13398  
Research Triangle Park, NC 27709  
Contact: Department of Consumer Affairs (800) 437-0992 X 7900.

END POINT

-----

Drug efficacy, toxicity.

PARTICIPATING UNITS

-----

0000003604:  
UCSD Treatment Center  
2760 Fifth Avenue / 3rd Floor  
San Diego, CA 92103-6329  
Contact: Ron Snyder (619) 543-8080  
OPEN 960916.

0000003605:  
Mount Zion Hospital of UCSF  
2300 Sutter Street / Suite 202  
San Francisco, CA 94115  
Contact: John Sayre (415) 885-7737  
OPEN 960916.

0000003462:  
San Francisco Veterans Administration Medical Center  
4150 Clement Street  
San Francisco, CA 94121  
Contact: Sandy Charles (415) 221-4810 X 3763  
OPEN 960916.

0000003609:  
AIDS Research Center  
Dept of Veterans Affairs / 3801 Miranda Avenue / III-ID  
Palo Alto, CA 94304  
Contact: Mark Mistal (415) 493-5000 X 64926  
OPEN 960916.

0000001499:  
University of Colorado Health Sciences Center  
4200 East 9th Avenue / Box B-163  
Denver, CO 80262  
Contact: M Graham Ray (303) 372-5535  
OPEN 960918.

0000003607:  
New England Medical Center  
750 Washington Street / NEMCH67  
Boston, MA 02111  
Contact: Charlene Gaca (617) 636-8186

OPEN 960916.

0000003594:

Harvard University / Massachusetts General Hospital  
55 Fruit Street / Gray 5  
Boston, MA 02114  
Contact: Ellen Godfrey McCarthy (617) 726-5598  
OPEN 960916.

0000003608:

Beth Israel Medical Center  
First Avenue at 16th Street  
New York, NY 10003  
Contact: Gwen Constantini (212) 420-4519  
OPEN 961021.

0000003606:

University of Texas Medical Branch  
Route 0835 / 301 University Boulevard  
Galveston, TX 77555-0835  
Contact: Phylliss Galatas (409) 747-0241  
OPEN 960916.

\*\*\*\*\*

PROTOCOL NUMBER: FDA 232C.

TITLE: A Multi-Center, Randomized, Double-Blind, Placebo-Controlled  
Study of the Efficacy and Safety of Adefovir Dipivoxil When  
Added to Standard Antiretroviral Therapy for the Treatment of  
HIV-Infected Patients With CD4 Cell Counts  $\geq 200/\text{mm}^3$ .

#### DISEASE STATUS:

Patients have the following symptoms and conditions: 1. HIV infection. 2. HIV RNA titer  $\geq 2500$  copies/ml (2.5 KEq/ml) plasma by branched DNA analysis within the past 2 weeks. 3. CD4 count  $\geq 200$  cells/mm<sup>3</sup> within the past month. 4. No new AIDS-defining event within the past 2 months. 5. Tolerated antiretroviral therapy for the past 2 months. NOTE: Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month.

#### PATIENT INCLUSION CRITERIA

-----

#### SPECIFICATION CRITERIA:

Patients must have:

1. HIV infection with HIV RNA titer  $\geq 2500$  copies/ml (2.5 KEq/ml) plasma.
2. CD4 count  $\geq 200$  cells/mm<sup>3</sup>.
3. No new AIDS-defining event within the past 2 months.
4. Life expectancy at least 1 year.
5. Consent of parent or guardian if less than 18 years old.
6. Tolerated antiretroviral therapy for the past 2 months.

NOTE: Kaposi's sarcoma is permitted provided patient has not received systemic therapy within the past month.

AGE: 13 Years - 99 Years.

SEX: M. F.

REPRODUCTIVE SPECIFICATION:

Not pregnant. Negative pregnancy test within 14 days of study entry.

Not breast-feeding. Abstinence or effective method of birth control / contraception including oral contraceptives during the study.

PRIOR MEDICATION:

Required: Antiretroviral therapy for at least the past 2 months.

CONCURRENT MEDICATION:

Required: Antiretroviral regimen other than study drug.

LABORATORY VALUES AT ENTRY

HEMOGLOBIN:  $\geq 8$  g/dl. (without hematologic growth factors).

PLATELET COUNT:  $\geq 50000$  platelets/mm<sup>3</sup>.

CD4 (T4 CELL) COUNT:  $\geq 200$  cells/mm<sup>3</sup>. ( 200 - 300 - 400 - 500 - 600 - 700 - 800 - plus ).

SGOT (AST):  $\leq 3 \times$  ULN. (ULN = upper limit of normal).

SGPT (ALT):  $\leq 3 \times$  ULN.

CREATININE:  $\leq 1.5 \times$  ULN.

KARNOFSKY:  $\geq 80$ .

OTHER LABORATORY VALUES: Absolute neutrophils  $\geq 750$  cells/mm<sup>3</sup>. Serum amylase  $\leq 1.5 \times$  ULN ( if serum amylase  $> 1.5 \times$  ULN, then pancreatic amylase or lipase  $< 1.5 \times$  ULN may be substituted).

PATIENT EXCLUSION CRITERIA

AGE: 01 Days - 12 Years.

REPRODUCTIVE SPECIFICATION:

Pregnant. Positive pregnancy test within 14 days of study entry.

Breast-feeding. No abstinence or no agreement to use effective method of birth control / contraception during the study.

RISK BEHAVIOR:

Current alcohol or substance abuse that would interfere with compliance.

PRIOR MEDICATION:

Excluded:

1. Parenteral antibiotic or antiviral therapy for another active, serious infection within the past 2 weeks.

2. Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons within the past month.
3. Systemic therapy for KS within the past month.

CONCURRENT MEDICATION:

Excluded:

1. Immunomodulating agents such as systemic corticosteroids, IL-2, or interferons.
2. Isoniazid.
3. Rifampin.
4. Investigational agents (unless approved by sponsor).
5. Systemic chemotherapeutic agents.

CO-EXISTING CONDITIONS OR DISEASES:

Patients with the following symptoms or conditions are excluded:

1. Active, serious infections other than HIV that require parenteral antibiotic or antiviral therapy.
2. Gastrointestinal malabsorption syndrome or chronic nausea or vomiting that would preclude oral medication.
3. Malignancy other than Kaposi's sarcoma or basal cell carcinoma.

GENERIC DRUG NAME

-----

Drug 1: Adefovir dipivoxil. Antiretroviral.

DRUG COMPANIES

-----

Drug 1: Gilead Sciences Incorporated  
353 Lakeside Drive  
Foster City, CA 94404  
Contact: Dr Jay Toole (415) 573-4751.

END POINT

-----

Drug efficacy, toxicity.

PARTICIPATING UNITS

-----

0000003593:  
University of Alabama at Birmingham  
908 20th Street South  
Birmingham, AL 35294-2041  
Contact: Betty McCulloch (205) 975-7925  
OPEN 960808.

0000002310:

Harbor - UCLA Medical Center  
1124 West Carson Street / Lab E2  
Torrance, CA 90502  
Contact: Sally Krueger (310) 533-3848  
OPEN 960808.

0000003567:  
Kraus Medical Partners  
5901 West Olympic Blvd / Suite 310  
Los Angeles, CA 90509  
Contact: Uni Kim (213) 930-2324  
OPEN 960808.

0000003571:  
Pacific Oaks Research  
4940 Van Nuys Boulevard / 2nd Floor  
Sherman Oaks, CA 91403  
Contact: Sindy Kim (818) 906-6279  
OPEN 960808.

0000003568:  
San Francisco General Hospital  
995 Potrero Avenue / Building 80 / Ward 84  
San Francisco, CA 94115  
Contact: Anna Smith (415) 476-4082 X 84098  
OPEN 960808.

0000003572:  
San Mateo County Medical Center / San Mateo County AIDS Prog  
3700 Edison Street  
San Mateo, CA 94403  
Contact: Brian Camp (415) 364-6563  
OPEN 960808.

0000003151:  
East Bay AIDS Center  
3031 Telegraph Avenue / Suite 235  
Berkeley, CA 94705  
Contact: Nancy Orcutt (510) 204-1291  
OPEN 960808.

0000002575:  
Santa Clara Valley Medical Center  
751 South Bascom Avenue  
San Jose, CA 95128-2699  
Contact: Carol Kane (408) 885-4316  
Contact: Dr Carol Kemper (assoc dir) (408) 885-4300  
OPEN 960808.

0000003509:  
Georgetown University Medical Center  
3800 Reservoir Road NW / Kober - Cogan Building / Suite 110  
Washington, DC 20007  
Contact: Irene Scanlon RN (202) 687-1079

Contact: (202) 687-6845  
OPEN 960808.

0000003570:  
Institute for Clinical Research  
50 Irving Street NW 151-B / VA Medical Center  
Washington, DC 20422  
Contact: Peg Lankford (202) 745-8000 X 5007  
Contact: Donna Mills  
OPEN 960808.

0000002252:  
University of South Florida  
5471 4th Street South  
St Petersburg, FL 33705  
Contact: Pat Seeley (813) 974-3163  
OPEN 960808.

0000003603:  
AIDS Research Consortium of Atlanta  
131 Ponce de Leon Avenue / Suite 130  
Atlanta, GA 30308  
Contact: Harriotte Bohn (404) 876-2317  
OPEN 960912.

0000003577:  
Chicago Center / Clinical Research  
515 North State Street / Suite 2700  
Chicago, IL 60610  
Contact: Julie Frowick (312) 494-2206  
OPEN 960808.

0000002777:  
Northwestern University  
303 East Superior Street / Passavant Pavilion / Room 828  
Chicago, IL 60611  
Contact: Pam Donath (312) 908-0949  
OPEN 960808.

0000003575:  
Tulane University / Tulane/LSU Clinical Trials Unit  
1430 Tulane Avenue  
New Orleans, LA 70122  
Contact: Dawn Morgado (504) 587-7316  
OPEN 960808.

0000003594:  
Harvard University / Massachusetts General Hospital  
55 Fruit Street / Gray 5  
Boston, MA 02114  
Contact: Ellen Godfrey McCarthy (617) 726-5598  
OPEN 960808.

0000003574:

Wayne State University / University Health Center  
Pod 6F 4201 Saint Antoine  
Detroit, MI 48201  
Contact: Helen Dries (313) 993-0926  
OPEN 960808.

0000002129:  
Carolinas Medical Center  
1000 Blythe Boulevard  
Charlotte, NC 28204  
Contact: Dr James Horton (704) 355-5292 X 3165  
Contact: Joan Connell (704) 355-5292  
OPEN 960808.

0000003579:  
Saint Vincent's Medical Center  
412 6th Avenue / Room 401  
New York, NY 10011  
Contact: M George (212) 228-8000  
OPEN 960808.

0000003602:  
Saint Vincent's Medical Center  
412 6th Avenue / Room 401  
New York, NY 10011  
Contact: Mary Katherine George (212) 228-8000  
OPEN 960912.

0000003578:  
Albany Medical College / Clinical Pharmacy Studies  
Unit A-142 / 47 New Scotland Avenue  
Albany, NY 12208  
Contact: Carol MacDonald (205) 975-6323  
OPEN 960808.

0000003601:  
The Research and Education Group  
2701 NW Vaughn / Suite 840  
Portland, OR 97210-5311  
Contact: Norma Martinez (503) 229-8428  
OPEN 960912.

0000003580:  
Vanderbilt University Medical Center  
Medical Arts Building / 1211 Twenty-first Ave S / Ste 539  
Nashville, TN 37212  
Contact: D Haas (615) 936-1174  
OPEN 960808.

0000003573:  
Dallas VA Medical Center  
4500 Lancaster Road  
Dallas, TX 75216  
Contact: Sherrie Norris (214) 648-3877

OPEN 960808.

0000003569:

Houston Clinical Research Network

1200 Binz / Suite 120

Houston, TX 77004

Contact: Barbara Griffin (713) 520-2000 X 211

OPEN 960808.

0000003576:

University of Texas

200 University Boulevard / Suite 518

Galveston, TX 77555-0835

Contact: Phyllis Galatas (409) 747-0241

OPEN 960808.

0000001480:

University of Utah School of Medicine

50 North Medical Drive / Room 4B 322

Salt Lake City, UT 84132

Contact: Susan Bracken (801) 581-4878

OPEN 960808.

0000002960:

University of Wisconsin

600 Highland Avenue / H-6/368 CSC

Madison, WI 53792

Contact: Jeff Howells (608) 265-5729

OPEN 960808.

\*\*\*\*\*

===== END ATTACHMENT 1 =====

===== ATTACHMENT 2 =====

ATT CREATION TIME/DATE:20-SEP-1996 16:33:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)

id <0119PIGLTLV40011G6@PMDF.EOP.GOV> for levi\_j@a1.eop.gov; Fri,

20 Sep 1996 16:33:09 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)

by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119PIGIQF5S000V71@PMDF.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 16:33:05 -0400 (EDT)

Received: from aspen3.aspensys.com (aspensys3.aspensys.com)

by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119PIDW690C00007L@STORM.EOP.GOV> for

levi\_j@a1.eop.gov; Fri, 20 Sep 1996 16:30:58 -0700 (MST)

Received: by aspen3.aspensys.com (SMI-8.6/SMI-SVR4) id QAA26910; Fri,

20 Sep 1996 16:33:05 -0400

Errors-to: shelly\_olim\_at\_aspenpo@smtpinet.aspensys.com

Precedence: bulk

Originator: [aidsnews@cdcnac.aspensys.com](mailto:aidsnews@cdcnac.aspensys.com)

X-Comment: CDC National AIDS Clearinghouse

X-Listprocessor-version: 6.0c -- ListProcessor by Anastasios Kotsikonas

===== END ATTACHMENT 2 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:23-SEP-1996 11:57:08.23

SUBJECT: Furniture and TV's

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:24-SEP-1996 10:19:19.25

TO: Janet B. Abrams ( ABRAMS\_J ) (VPO)  
READ:24-SEP-1996 10:09:40.84

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:23-SEP-1996 12:00:26.06

TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S ) (OPD)  
READ:24-SEP-1996 09:49:48.36

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:23-SEP-1996 13:11:37.73

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:24-SEP-1996 10:03:05.93

TO: Julie E. Demeo ( DEMEO\_J )  
READ:NOT READ

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:07:26.42

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:23-SEP-1996 12:29:46.36

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:23-SEP-1996 11:59:25.37

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ:23-SEP-1996 16:26:35.59

TO: Dorothy L. Karayannis ( KARAYANNIS\_D )  
READ:NOT READ

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:24-SEP-1996 09:14:42.85

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:23-SEP-1996 12:12:44.21

TO: Cathy R. Mays ( MAYS\_C ) (OPD)  
READ:23-SEP-1996 11:58:05.82

TO: Rosalyn A. Miller ( MILLER\_RA )  
READ:NOT READ

TO: Bruce N. Reed ( REED\_B ) (WHO)  
READ:23-SEP-1996 11:58:44.00

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:23-SEP-1996 11:57:44.81

TO: Denise Ricketson ( RICKETSON\_D )  
READ:NOT READ

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:23-SEP-1996 12:00:24.61

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:23-SEP-1996 12:02:40.28

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:23-SEP-1996 12:32:50.54

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:23-SEP-1996 12:42:31.69

TO: Claudia M. Rayford-Williams ( RAYFORDWIL\_C ) (OPD)  
READ:23-SEP-1996 12:45:29.03

TO: Deborah L. Fine ( FINE\_D ) (OPD)  
READ:24-SEP-1996 09:10:52.17

TEXT:

Please let me know today if you would like a large set of shelves with solid wood doors. The unit is currently in Lyn's office and has to be moved out by Wednesday. If no one is interested, we will surplus it. THAnks.

Also, please let make corrections as appropriate to the list below of those who have televisions:

Brostrom  
Burke  
Rayford-Williams  
Drye  
Hogan  
Jennings (1)  
Klein (?)  
Reed  
Regas  
Warnath  
Weinstein  
Rasco  
Cohen

Thanks.

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 11:18:48.41

SUBJECT: scheduling model

TO: Ursula Sanville ( SANVILLE\_U ) (OPD)

READ:23-SEP-1996 12:11:27.55

TEXT:

see n:quilt.ske

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jeffrey Levi ( LEVI\_J ) (WHO)

CREATION DATE/TIME:23-SEP-1996 09:01:46.18

SUBJECT: dilemma

TO: Remote Addressee ( critter@hcfa.gov@INET )  
READ:NOT READ

TEXT:

Chris -- it looks great; you did a wonderful job; you were, of course, more thorough than any of us would have been. Thanks!

RECORD TYPE: PRESIDENTIAL (EXTERNAL MAIL)

CREATOR: neb@s-3.com@INET@EOPMRX

CREATION DATE/TIME:24-SEP-1996 15:46:00.00

SUBJECT: Federal Plan

TO: 'smtp:LEVI\_J@a1.eop.gov' ( LEVI\_J@A1@CD ) (WHO)  
READ:25-SEP-1996 08:57:51.99

CC: Farrell, Kimberly ( KSF@FromPo1.s-3.com@INET@EOPMRX )  
READ:NOT READ

CC: Van Ness, Peggy ( MRV@FromPo1.s-3.com@INET@EOPMRX )  
READ:NOT READ

TEXT:

Please let me know the status of approval for printing the Federal Plan.  
The OAR would like to have it available at the OARAC meeting in October.  
Thank you.

===== ATTACHMENT 1 =====  
ATT CREATION TIME/DATE:24-SEP-1996 15:47:00.00

ATT BODYPART TYPE:D

TEXT:

RFC-822-headers:

Received: from conversion.pmdf.eop.gov by PMDF.EOP.GOV (PMDF V5.0-4 #6879)  
id <0119V1Y3QVB4001T2F@PMDF.EOP.GOV> for LEVI\_J@a1.eop.gov; Tue,  
24 Sep 1996 15:46:01 -0400 (EDT)

Received: from storm.eop.gov (storm.eop.gov)  
by PMDF.EOP.GOV (PMDF V5.0-4 #6879) id <0119V1Y2Z9V4001X74@PMDF.EOP.GOV> for  
LEVI\_J@a1.eop.gov; Tue, 24 Sep 1996 15:45:37 -0400 (EDT)

Received: from 206.65.240.10 (206.65.240.10)  
by STORM.EOP.GOV (PMDF V5.0-7 #6879) id <0119V1S3THHU00007K@STORM.EOP.GOV> for  
LEVI\_J@a1.eop.gov; Tue, 24 Sep 1996 15:40:55 -0700 (MST)

Received: from SSSHQ5 ([206.65.240.10])  
by ssshq5.s-3.com (post.office MTA v2.0 0813 ID# 0-18294U110)  
with SMTP id AAA42 for <LEVI\_J@a1.eop.gov>; Tue, 24 Sep 1996 11:54:36 -0400

X-Mailer: Worldtalk (NetConnex V4.00a)/MIME

===== END ATTACHMENT 1 =====

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

CREATION DATE/TIME:24-SEP-1996 12:53:22.04

SUBJECT: UGH - re: Tickler

TO: Janet B. Abrams ( ABRAMS\_J ) (VPO)  
READ:24-SEP-1996 15:12:16.54

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:24-SEP-1996 13:44:20.27

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:24-SEP-1996 14:00:14.56

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:24-SEP-1996 13:13:43.02

TO: Pamela Cicetti ( CICETTI\_P ) (WHO)  
READ:24-SEP-1996 13:06:10.36

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:24-SEP-1996 14:17:47.27

TO: Deborah L. Fine ( FINE\_D ) (OPD)  
READ:24-SEP-1996 12:54:13.11

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:24-SEP-1996 13:05:54.19

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ: 2-OCT-1996 15:26:34.33

TO: Dorothy K. Craft ( CRAFT\_D ) (OPD)  
READ:24-SEP-1996 13:21:01.28

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:24-SEP-1996 14:16:23.42

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:25-SEP-1996 08:57:37.75

TO: Cathy R. Mays ( MAYS\_C ) (OPD)  
READ:24-SEP-1996 12:59:07.91

TO: Carol H. Rasco ( RASCO\_C ) (WHO)  
READ:25-SEP-1996 08:34:22.63

TO: Bruce N. Reed ( REED\_B ) (WHO)  
READ:24-SEP-1996 13:01:40.35

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:24-SEP-1996 12:53:55.99

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:24-SEP-1996 13:04:54.65

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:24-SEP-1996 13:18:42.10

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:24-SEP-1996 12:58:33.51

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:24-SEP-1996 22:21:55.15

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:24-SEP-1996 14:07:40.22

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:24-SEP-1996 12:57:50.13

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:09:16.39

TO: Claudia M. Rayford-Williams ( RAYFORDWIL\_C ) (OPD)  
READ:24-SEP-1996 14:20:08.45

TEXT:

... my apologies to everyone for resending this. Here is the most updated version of the tickler that I should have forwarded. thanks.

PRINTER FONT 12\_POINT\_COURIER  
TICKLER FILE (as of September 13, 1996)  
ABRAMS, JANET  
BEN - AMI, JEREMY

BROSTROM, MOLLY  
BURKE, DENNIS

- \*9/11 - status of POTUS response to Califano letter
- \*8/21 - comment on proposed regulatory changes to the Juvenile Justice and Delinquency Prevention Act
- \*8/6 - response to NY State Alliance of Info. & Referral Systems concerning non

-emergency 911 calls.  
\*7/29 - Penn. Assoc. for Information & Referral (PAIR)to aid

the POTUS' plan for easing non

-emergency 911 calls  
\*7/15 - response on the support of upcoming legislation on Character Research and Therapy  
\*5/24 - response to Distilled Spirits Council of US and its

support of the 1996 Nat'l Drug Control Strategy

\*4/29 - draft brief on RAMS program

\*2/29 - follow

-up to South Florida HIDTA program

CICETTI, PAM

COHEN, MIKE

\*9/13 - status of grant for Edcouch - Elsa School District

(Delta Area Empowerment Sub

-Zone)

\*8/6 - follow

-up to Jamie Frakes' fax / Higher Education Act

\*7/17 - response regarding memo to POTUS regrading Fred

Taylor

CRAFT, DOROTHY K.

\*9/17 - response to sixth grade class'project on world

hunger

DEMEO, JULIE

DRYE, ELIZABETH

\*9/13 - discussion on fax/ issues from Nat'l Assoc. of State

Alcohol and Drug Abuse Directors

\*7/30 - reply to request for POTUS to support Oregon's plan  
for universal health care

FINE, DEBBIE

FLEMING, PATSY

FORTUNA, DIANA

\*9/13 - response to Richard Dietrich's letter to POTUS

concerning wife w/ muscular dystrophy and transportation  
needs

\*9/11 - status of POTUS response to Sen. Kent Conrad's  
letter regarding the SSI provisions of welfare

\*8/23 - reply to the Arkansas Early Childhood Commission  
after feedback from HHS

\*7/29 - reply to ALPHA Communities, Inc. with their concerns

about funding and their desires to advance their program

\*7/14 - response to Family Voices/Polly Arango

HOGAN, LYN

JENNINGS, CHRIS

KLEIN, JENNIFER

LEVI, JEFF

PIZZUTO, JILL

\*9/16 - coordiante response with POTUS correspondence to

IDEA Act from Illinois Planning Council on Developmental  
Disabilities

\*9/9 - requests to Carmen Fowler and Jim Dorskind's office  
in reference to needed letters of support for various  
upcoming events; Fowler's request incomplete, request to  
Dorskind's office complete, but waiting for cc - follow

-up  
needed.

SMARTT, JEANINE

WARNATH, STEVE

\*9/10 - answer to POTUS on Golden Venture Detainees Issue

\*5/28 - discussion on DPC draft concerning benefits for  
illegal and legal immigrants

\*3/11 - reply to People of the Golden Vision concerning the

status of the immigrants of the Golden Venture detained by INS

WEINSTEIN, PAUL

\*5/10 - continued follow

-up on the RGV Empowerment Zone

\*3/11 - follow

-up on letter from Sen. Lockyer's office  
concerning the proposed reform legislation and ensuring the  
protection of child welfare

#### OTHER WHITE HOUSE STAFF

BROMBERG, EMILY

\*9/11 - handling Chiles letter as per Jeremy's request

O'CONNOR, JENNIFER

\*8/21 - formulate response (if needed) to Nat'l Assoc. of  
Evangelicals concerning tobacco legislation.

SHEA, TOM

\*9/23 - response to Iowa tribe of Oklahoma concernig the  
University of Missouri's possession of Native American  
remains

#### POTUS

\*6/25 - reply to get presidential recognition for Theodore  
Sizer

\*6/27 - response to thank Lincoln Steed for his letter  
concerning his publication's story on the Rasco family

\*7/8 - letter to Mayor of Albany's niece after Carol Rasco's

visit to area and Enterprise Community

\*7/25 - response to the opposiotn letter of the Consortium  
for Citizens with Disabilities concerning the  
physicians in the Medicaids and Medicare managed care  
programs

\*8/5 - letter to retiring member of the Arkansas Dept. of  
Correction

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Jill Pizzuto ( PIZZUTO\_J ) (OPD)

CREATION DATE/TIME:24-SEP-1996 10:21:04.09

SUBJECT: TICKLER FILE

TO: janet B. Abrams ( ABRAMS\_J ) (VPO)  
READ:24-SEP-1996 12:08:44.51

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:24-SEP-1996 10:39:18.44

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:24-SEP-1996 10:36:28.42

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:24-SEP-1996 10:38:56.39

TO: Pamela Cicetti ( CICETTI\_P ) (WHO)  
READ:24-SEP-1996 10:55:23.94

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:24-SEP-1996 12:41:59.41

TO: Deborah L. Fine ( FINE\_D ) (OPD)  
READ:24-SEP-1996 10:32:16.18

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:24-SEP-1996 10:24:46.42

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ: 2-OCT-1996 15:26:20.24

TO: Dorothy K. Craft ( CRAFT\_D ) (OPD)  
READ:24-SEP-1996 10:22:41.02

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:24-SEP-1996 11:27:25.37

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:25-SEP-1996 08:56:43.99

TO: Cathy R. Mays ( MAYS\_C ) (OPD)  
READ:24-SEP-1996 10:32:01.55

TO: Carol H. Rasco ( RASCO\_C ) (WHO)  
READ:25-SEP-1996 07:26:44.95

TO: Bruce N. Reed ( REED\_B ) (WHO)  
READ:24-SEP-1996 10:38:34.10

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:24-SEP-1996 10:27:43.71

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:24-SEP-1996 10:46:43.47

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:24-SEP-1996 11:28:21.38

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:24-SEP-1996 11:33:46.74

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:24-SEP-1996 22:17:40.74

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:24-SEP-1996 13:36:58.33

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:NOT READ

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:08:16.40

TO: Claudia M. Rayford-Williams ( RAYFORDWIL\_C ) (OPD)  
READ:24-SEP-1996 10:35:29.51

TEXT:  
fyi: attached is the tickler. Please email or call Jennifer  
6

-5565 w/ updates.

thanks.

PRINTER FONT 12\_POINT\_COURIER

TICKLER FILE (as of September 13, 1996)

ABRAMS, JANET

BEN - AMI, JEREMY

- \*9/11 - handling of Lawton Chiles' letter about food stamps  
(waiver options) for legal noncitizens (in FL.)

BROSTROM, MOLLY

BURKE, DENNIS

- \*9/11 - status of POTUS response to Califano letter

- \*8/21 - comment on proposed regulatory changes to the  
Juvenile Justice and Delinquency Prevention Act

- \*8/6 - response to NY State Alliance of Info. & Referral  
Systems concerning non

-emergency 911 calls.

- \*7/29 - Penn. Assoc. for Information & Referral (PAIR) to aid

the POTUS' plan for easing non

-emergency 911 calls

- \*7/15 - response on the support of upcoming legislation on

Character Research and Therapy

\*5/24 - response to Distilled Spirits Council of US and its support of the 1996 Nat'l Drug Control Strategy0

\*4/29 - draft brief on RAMS program

\*3/5 - reply call concerning TAG Foundation to Peter

Schwartz

\*2/29 - follow

-up to South Florida HIDTA program

CICETTI, PAM

COHEN, MIKE

\*8/6 - follow

-up to Jamie Frakes' fax / Higher Education Act

\*7/17 - response regarding memo to POTUS regrading Fred

Taylor

CRAFT, DOROTHY K.

DEMEO, JULIE

DRYE, ELIZABETH

\*8/21 - appropriate staff to draft response to David Jones concerning the Vancomycin issue

\*8/1 - response to Iowa Tribe of Oklahoma concerning the Univ. of Missouri's possession of Native American remains

\*7/30 - reply to request for POTUS to support Oregon's plan for universal health care

\*7/21 - thank you to ellsworth productions, inc. concerning the children's video about welfare reform

\*7/3 - draft response to Phil English's request for support

of the creation of an independent Medicare comminssion  
legislation

FINE, DEBBIE

FLEMING, PATSY

FORTUNA, DIANA

\*9/11 - status of POTUS response to Sen. Kent Conrad's letter regarding the SSI provisions of welfare

\*9/11 - set

-up meeting with Barbara Otto, re: SSI

\*9/3 - SEE ABOVE - set up meeting with the SSI Coalition concerning the new definition of disability and its effects on children

\*8/23 - reply to the Arkansas Early Childhood Commission after feedback from HHS

\*7/29 - reply to ALPHA Communities, Inc. with their concerns

about funding and their desires to advance their program

\*7/14 - response to Family Voices/Polly Arango

HOGAN, LYN

\*7/24 - reply to letter from Center for Family Connections hoping to maintain in communication

JENNINGS, CHRIS

KLEIN, JENNIFER

LEVI, JEFF

PIZZUTO, JILL

\*9/9 - requests to Carmen Fowler and Jim Dorskind's office  
in reference to needed letters of support for various  
upcoming events; Fowler's request incomplete, request to  
Dorskind's office complete, but waiting for cc - follow

-up

needed.

SMARTT, JEANINE

WARNATH, STEVE

\*9/10 - answer to POTUS on Golden Venture Detainees Issue

\*5/28 - discussion on DPC draft concerning benefits for  
illegal and legal immigrants

\*3/11 - reply to People of the Golden Vision concerning the

status of the immigrants of the Golden Venture detained by INS

WEINSTEIN, PAUL

\*5/10 - continued follow

-up on the RGV Empowerment Zone

\*3/11 - follow

-up on letter from Sen. Lockyer's office  
concerning the proposed reform legislation and ensuring the  
protection of child welfare

OTHER WHITE HOUSE STAFF

O'CONNOR, JENNIFER

\*8/21 - formulate response (if needed) to Nat'l Assoc. of  
Evangelicals concerning tobacco legislation.

POTUS

\*6/25 - reply to get presidential recognition for Theodore  
Sizer

\*6/27 - response to thank Lincoln Steed for his letter  
concerning his publication's story on the Rasco family

\*7/8 - letter to Mayor of Albany's niece after Carol Rasco's

visit to area and Enterprise Community

\*7/25 - response to the opposiotn letter of the Consortium  
for Citizens with Disabilities concerning the  
physicians in the Medicaids and Medicare managed care  
programs

\*8/5 - letter to retiring member of the Arkansas Dept. of  
Correction

RECORD TYPE: PRESIDENTIAL (ALL-IN-1 MAIL)

CREATOR: Elizabeth E. Drye ( DRYE\_E ) (OPD)

CREATION DATE/TIME:24-SEP-1996 12:12:29.11

SUBJECT: Hot Issues

TO: Elizabeth E. Drye ( DRYE\_E ) (OPD)  
READ:24-SEP-1996 12:44:05.60

TO: Jeremy D. Benami ( BENAMI\_J ) (WHO)  
READ:NOT READ

TO: Molly Brostrom ( BROSTROM\_M ) (WHO)  
READ:24-SEP-1996 13:58:21.42

TO: Dennis Burke ( BURKE\_D ) (OPD)  
READ:24-SEP-1996 12:13:25.73

TO: Diane Regas ( REGAS\_D ) (OPD)  
READ:24-SEP-1996 12:19:11.38

TO: Patsy Fleming ( FLEMING\_P ) (WHO)  
READ:24-SEP-1996 14:08:31.46

TO: Diana M. Fortuna ( FORTUNA\_D ) (OPD)  
READ:24-SEP-1996 13:10:36.32

TO: Christopher C. Jennings ( JENNINGS\_C ) (WHO)  
READ:24-SEP-1996 19:54:00.10

TO: Jennifer L. Klein ( KLEIN\_J ) (OPD)  
READ:24-SEP-1996 12:17:02.73

TO: Jeffrey Levi ( LEVI\_J ) (WHO)  
READ:25-SEP-1996 08:57:18.61

TO: Jill Pizzuto ( PIZZUTO\_J ) (OPD)  
READ:24-SEP-1996 12:20:02.87

TO: Stephen C. Warnath ( WARNATH\_S ) (OPD)  
READ:24-SEP-1996 12:13:45.46

TO: Paul J. Weinstein, Jr ( WEINSTEIN\_P ) (OPD)  
READ:24-SEP-1996 13:18:18.74

TO: Lyndell Hogan ( HOGAN\_L ) (OPD)  
READ:24-SEP-1996 12:42:18.80

TO: Jeanine D. Smartt ( SMARTT\_J ) (OPD)  
READ:24-SEP-1996 22:21:11.75

TO: Michael Cohen ( COHEN\_M ) (OPD)  
READ:24-SEP-1996 13:39:43.56

TO: Sandra L. Bublick-Max ( BUBLICKMAX\_S ) (OPD)  
READ:24-SEP-1996 15:52:10.61

TEXT:

Please let me know today if you have any issues for these destinations we should cover or I should make sure cab affairs has agencies cover. Thanks.

===== ATTACHMENT 1 =====

ATT CREATION TIME/DATE:23-SEP-1996 16:09:00.00

ATT CREATOR: Helen P. Howell

ATT SUBJECT: Texas/Rhode Island/Massachusetts Trip

ATT TO: John C. Angell ( ANGELL\_J )  
ATT TO: Kris Balderston ( BALDERSTON\_K )  
ATT TO: David S. Beaubaire ( BEAUBAIRE\_D )  
ATT TO: Jeremy D. Benami ( BENAMI\_J )  
ATT TO: Debra D. Bird ( BIRD\_D )  
ATT TO: Alison Bracewell ( BRACEWELL\_A )  
ATT TO: Dennis Burke ( BURKE\_D )  
ATT TO: Gabrielle M. Bushman ( BUSHMAN\_G )  
ATT TO: Phillip M. Caplan ( CAPLAN\_P )  
ATT TO: Julia E. Chamovitz ( CHAMOVITZ\_J )  
ATT TO: Carolyn E. Cleveland ( CLEVELAND\_C )  
ATT TO: Daniel P. Collins ( COLLINS\_D )  
ATT TO: Catherine A. Cornelius ( CORNELIUS\_C )  
ATT TO: Amanda Crumley ( CRUMLEY\_A )  
ATT TO: Marilyn DiGiacobbe ( DIGIACOBBE\_M )  
ATT TO: J. Fred Dohse ( DOHSE\_J )  
ATT TO: Elizabeth E. Drye ( DRYE\_E )  
ATT TO: Jennifer D. Dudley ( DUDLEY\_J )  
ATT TO: Anne M. Edwards ( EDWARDS\_A )

|                             |                 |
|-----------------------------|-----------------|
| ATT TO: Nicole Elkon        | ( ELKON_N )     |
| ATT TO: Rahm Emanuel        | ( EMANUEL_R )   |
| ATT TO: Janice A. Enright   | ( ENRIGHT_J )   |
| ATT TO: Eric Eve            | ( EVE_E )       |
| ATT TO: Shelley N. Fidler   | ( FIDLER_S )    |
| ATT TO: Stacy L. Forster    | ( FORSTER_S )   |
| ATT TO: Andrew Friendly     | ( FRIENDLY_A )  |
| ATT TO: Jeremy M. Gaines    | ( GAINES_J )    |
| ATT TO: Mary Ellen Glynn    | ( GLYNN_M )     |
| ATT TO: Jason S. Goldberg   | ( GOLDBERG_JS ) |
| ATT TO: David S. Goodin     | ( GOODIN_D )    |
| ATT TO: Julia R. Green      | ( GREEN_J )     |
| ATT TO: Karen L. Hancox     | ( HANCOX_K )    |
| ATT TO: Cookab Hashemi      | ( HASHEMI_C )   |
| ATT TO: Anne Hawley         | ( HAWLEY_A )    |
| ATT TO: Nancy V. Hernreich  | ( HERNREICH_N ) |
| ATT TO: Russell W. Horwitz  | ( HORWITZ_R )   |
| ATT TO: Phu D. Huynh        | ( HUYNH_P )     |
| ATT TO: Brian J. Johnson    | ( JOHNSON_BJ )  |
| ATT TO: Loreen M. Keller    | ( KELLER_L )    |
| ATT TO: Evelyn S. Lieberman | ( LIEBERMAN_E ) |
| ATT TO: Bruce R. Lindsey    | ( LINDSEY_B )   |
| ATT TO: Gordon Li           | ( LI_G )        |
| ATT TO: Ray Martinez        | ( MARTINEZ_R )  |
| ATT TO: Julie E. Mason      | ( MASON_J )     |
| ATT TO: Floydetta McAfee    | ( MCAFEE_F )    |
| ATT TO: Anne E. McGuire     | ( MCGUIRE_A )   |

|                              |                  |
|------------------------------|------------------|
| ATT TO: Lorraine McHugh      | ( MCHUGH_L )     |
| ATT TO: Kathy McKiernan      | ( MCKIERNAN_K )  |
| ATT TO: APRIL K. MELLODY     | ( MELLODY_A )    |
| ATT TO: Cathy L. Millison    | ( MILLISON_C )   |
| ATT TO: Julia Moffett        | ( MOFFETT_J )    |
| ATT TO: Linda L. Moore       | ( MOORE_L )      |
| ATT TO: David J. Morehouse   | ( MOREHOUSE_D )  |
| ATT TO: Ruby G. Moy          | ( MOY_R )        |
| ATT TO: Lucie F. Naphin      | ( NAPHIN_L )     |
| ATT TO: Jonathan Orszag      | ( ORSZAG_J )     |
| ATT TO: Jennifer Palmieri    | ( PALMIERI_J )   |
| ATT TO: Christa T. Robinson  | ( ROBINSON_C )   |
| ATT TO: Rica F. Rodman       | ( RODMAN_R )     |
| ATT TO: Dan Rosenthal        | ( ROSENTHAL_D )  |
| ATT TO: James S. Rubin       | ( RUBIN_J )      |
| ATT TO: Lee A. Satterfield   | ( SATTERFIEL_L ) |
| ATT TO: Laura D. Schwartz    | ( SCHWARTZ_L )   |
| ATT TO: Andrew D. Sens       | ( SENS_A )       |
| ATT TO: Joshua Silverman     | ( SILVERMAN_J )  |
| ATT TO: Stephen B. Silverman | ( SILVERMAN_S )  |
| ATT TO: Wendy L. Smith       | ( SMITH_WL )     |
| ATT TO: Patrick M. Steel     | ( STEEL_P )      |
| ATT TO: Todd Stern           | ( STERN_T )      |
| ATT TO: Stephanie Streett    | ( STREETT_S )    |
| ATT TO: Daniel Taberski      | ( TABERSKI_D )   |
| ATT TO: Virginia M. Terzano  | ( TERZANO_V )    |
| ATT TO: Joe Trahern          | ( TRAHERN_J )    |

ATT TO: Sharon E. Wagner ( WAGNER\_S )  
ATT TO: Michael Waldman ( WALDMAN\_M )  
ATT TO: Ann F. Walker ( WALKER\_A )  
ATT TO: Anne S. Walker ( WALKER\_AS )  
ATT TO: Christopher F. Walker ( WALKER\_C )  
ATT TO: Kathleen M. Wallman ( WALLMAN\_KM )  
ATT TO: Dorian V. Weaver ( WEAVER\_D )  
ATT TO: Daniel Wexler ( WEXLER\_D )  
ATT TO: Allison Wilkie ( WILKIE\_A )  
ATT TO: David Wofford ( WOFFORD\_D )

TEXT:

POTUS will travel to the following cities on his trip:

- Longview, Texas
- Fort Worth, Texas
- Houston, Texas
- Providence, Rhode Island
- Fall River, Massachusetts
- Boston, Massachusetts

(Note that New Hampshire may be added to this trip also.)

Deadlines for the President's trip book are:

BACKGROUND MEMOS -- THURSDAY, September 26, 1996 at 12:00 noon.

Political Memo  
Economic Background  
1 Pagers  
Staple Prices  
Local Issues  
Cabinet Affairs Hot Issues  
Crime 1 Pagers  
Environmental Issues

EVENT MEMOS -- THURSDAY, September 26, 1996 at 4:00 p.m.

Thanks!!!!

===== END ATTACHMENT 1 =====